???global.info.a_carregar???
Carmen Jerónimo is the Director of the Research Center, Group Leader of the Cancer Biology & Epigenetics Group and the Scientific Coordinator of the Biobank at the Portuguese Oncology Institute of Porto (IPO Porto), as well as a guest Full Professor in the Department of Pathology and Molecular Genetics and the Director of the Master Course in Oncology at the University of Porto, teaching Pathology and Cancer Epigenetics, both undergraduate and Post-graduation Courses. She obtained her BSc in Biology (1994), MSc in Oncology (1998), PhD in Biomedical Sciences (2001), and Habilitation in Pathology and Molecular Genetics (2011) at the University of Porto. She performed her PhD project at Johns Hopkins University (JHU), USA under the GABBA Program, working on prostate cancer genetic and epigenetic alterations. From 2002 until 2007, she was a Post-doctoral Fellow and Invited Researcher at IPO Porto, in collaboration with JHU, working on the detection of neoplastic cells by DNA-based technology in clinical samples obtained from non-invasive or minimally invasive methods. In 2008 she established her independent group at IPO Porto, working on Cancer Biology and Epigenetics (FCT-2008 Science Program). She has supervised/co-supervised 14 PhD students, 77 master's students and several undergraduate students. Presently she mentors 2 Junior Researchers (R2), 15 PhD students (7 as co-supervisor), and 6 Master students. As an independent Researcher, she served as PI/co-PI of more than 20 grants. She participated in 14 other projects granted from different National and International agencies under competitive concurrence (> 6M euros). She has authored/ co-authored more than 300 international scientific publications including 13 book chapters and 84 review articles (H-index 55; WoS 12/2023), including in first quartile (Q1) journals; Clin Cancer Res, Cancers, Cancer Letters, Cell Death Dis, Clinical Epig, Br J Cancer, Eur J Cancer, J Cell Mol Med, J Hematol Oncol, JNCI, Mol Cancer, Mol Oncol and Nat Commun, Oncogene, PNAS]. In 2012 she collaborated on a patent submission (Methods and biomarkers for detection of bladder cancer US 20130210011/ EP 2630261 A1/ WO 2012052844 A1). Her research interests are focused on characterizing the epigenome of tumor cells and identifying functional changes involved in cell epigenetic homeostasis breakdown. In the context of Personalized Medicine, she works on developing new cancer epigenetic biomarkers based on liquid biopsies and drug discovery based on the modulation of epigenetic aberrations. Owing to the relevance that Immuno-oncology has demonstrated in recent years, she is also investigating the epigenetic expression modulation of biomolecules involved in immune checkpoint regulation, aiming to improve immunotherapeutic strategies combined with epi-drugs. More recently, she started tackling the contribution of deregulated non-coding RNAs and their interaction with other epigenetic mechanisms in malignant transformation. Currently, she serves as Section Editor of Clinical Epigenetics and Associate Editor of Frontiers in Genetics and Frontiers in Cell and Developmental Biology. She is also an MC member of COST Action European Epitranscriptomics Network- CA16120-EPITRAN and Chair of the Board- Section of Urological Research (ESUR) of the European Association of Urology (EAU). She usually acts as a grant reviewer for multiple national (FCT Investigator Call 2013 e 2015) and international agencies including Cancer Research UK; Binational Science Foundation Israel; Swiss National Science Foundation, WILLIAMS BARKER, MRC, UK; Swiss League Against Cancer-KFS; FWF Austrian Science Fund; PROSTATE CANCER UK; Agence Nationale de la Recherche, FR; Fundaciò La Marató, SP; Fonds National de la Recherche Luxembourg; Institut National Du Cancer, France; Novo Nordik Foden, Norway.
Identificação

Identificação pessoal

Nome completo
Carmen Jerónimo
Data de nascimento
1972/06/02
Género
Feminino

Nomes de citação

  • Jerónimo, Carmen

Identificadores de autor

Ciência ID
CE16-29CB-EDD1
ORCID iD
0000-0003-4186-5345
Researcher Id
H-3284-2013
Scopus Author Id
57197057169

Endereços de correio eletrónico

  • carmenjeronimo@ipoporto.min-saude.pt (Profissional)
  • cljeronimo@icbas.up.pt (Profissional)

Telefones

Telefone
  • 2250884000 Ext.: 7264 (Profissional)

Moradas

  • Centro de Investigação (LAB 3); Instituto Português de Oncologia do Porto de Francisco Gentil, E.P.E.. R. Dr. António Bernardino de Almeida, 4200-072, Porto, Porto, Portugal (Profissional)

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Básica - Genética Humana
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Diagnóstico e Terapias de Base Genética
  • Ciências Médicas e da Saúde - Medicina Básica - Farmacologia e Farmácia
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Tecnologias que envolvem a Manipulação de Células,Tecidos,Órgãos ou todo o Organismo
  • Ciências Médicas e da Saúde - Medicina Básica - Patologia

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Português Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Francês Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1)
Espanhol; Castelhano Utilizador independente (B1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador independente (B2)
Formação
Grau Classificação
2011/11/17
Concluído
Habilitation (Agregação) for full professorship in Pathology and Molecular Genetics/ Patologia e Genética Molecular (Título de Agregado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Curricular Unit:Cancer and Epigenetics ; Lesson: Development of epigenetic biomarkers for detection of urologic tumors" (TESE/DISSERTAÇÃO)
Approved by unanimity
1997/09 - 2001/10/24
Concluído
PhD in Biomedical Sciences/Ciências Biomédicas (Doutoramento)
Especialização em Cancer Genetics & Epigenetics
Universidade do Porto, Portugal
"Molecular Detection of Prostate Cancer" (TESE/DISSERTAÇÃO)
Approved by unanimity
1998
Concluído
MSc in Oncology/Oncologia (Mestrado)
Especialização em Molecular Oncology/Oncologia Molecular
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
""Transitional cell carcinoma of the Bladder: expression of p53, bcl-2, nm23, CD44s, CD44v6, and BL2-10D1 and their relation to histologic grade and stage"" (TESE/DISSERTAÇÃO)
Very Good by unanimity
1994
Concluído
BSc in Biology/Biologia (Licenciatura)
Especialização em Ramo Científico-Tecnológico
Universidade do Porto Faculdade de Ciências, Portugal
"n/a" (TESE/DISSERTAÇÃO)
14,45 (out of 20)
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento
Empregador
2009/07/01 - Atual Investigador Auxiliar (carreira) (Investigação) Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2004/10/01 - 2009/06/30 Investigador Auxiliar Convidado (carreira) (Investigação) Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2003/07/01 - 2003/12/31 Investigador visitante (Investigação) The Johns Hopkins University School of Medicine, Estados Unidos
The Johns Hopkins University School of Medicine, Estados Unidos

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento
Empregador
2020/09/01 - Atual Professor Catedrático Convidado (Docente Universitário) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021/03/01 - 2021/06/30 Professor Visitante (Docente Universitário) Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Medicina di Precisione, Itália
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Medicina di Precisione, Itália
2009/09/01 - 2020/08/31 Professor Associado Convidado (Docente Universitário) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013 - 2016 Professor Visitante (Docente Universitário) Universidade do Porto Faculdade de Medicina, Portugal
2004/09/01 - 2009/06/30 Professor Auxiliar (Docente Universitário) Universidade Fernando Pessoa, Portugal
2006 - 2009 Professor Auxiliar Convidado (Docente Universitário) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Cargos e Funções

Categoria Profissional
Instituição de acolhimento
Empregador
2021/11/01 - Atual Director of the IPO Porto Research Center (CI-IPOP) Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2021 - Atual Member of the executive board of RISE & coordinator of the thematic line-Cancer Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
RISE - Health Research Network, Portugal
(...)
2021 - Atual Member of the Joint Management Committee of the Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
(...)
2016/09/24 - Atual Director of the Master in Oncology Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016/09 - Atual President of the Scientific Committee of the Master course in Oncology Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016/01/01 - Atual Scientific coordinator of the IPO Porto' Biobank Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2008/01/01 - Atual Scientific coordinator of the Cancer Biology & Epigenetics Group Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2008/01/01 - Atual IPO Porto Research Center Scientific commitee Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2012/08 - 2016 Member of the Scientific Committee of the Master course in Oncology Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Outros

Categoria Profissional
Instituição de acolhimento
Empregador
2002/10/01 - 2004/08/31 Post-Doctoral fellow (FCT Grant SFRH/BPD/8031/2002) Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
1997/10/01 - 2001/09/30 PhD Student; FCT fellowship-PRAXIS XXI/BD/13398/97 Fundação para a Ciência e a Tecnologia, Portugal
The Johns Hopkins University School of Medicine, Estados Unidos
(...)
1996/09/01 - 1997/09/30 MSc Student; FCT Fellowship-PRAXIS XXI Grant BM/8579/96 Fundação para a Ciência e a Tecnologia, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
(...)
1994/09 - 1995/02 BSc Trainee; Scholarship PRODEP II (1/3.2/PRODEP/1993) Universidade do Porto Faculdade de Ciências, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Projetos

Bolsa

Designação Financiadores
2019 - Atual MindGAP: Bridging the gap between Mind, Brain and Body: exosome role and monitoring
H2020-FETOPEN-2018-2020
10.3030/829040
WP leader
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

University of Oulu, Finland, Finlândia

Universidade de Coimbra Departamento de Engenharia Quimica, Portugal

Linneuniversitet Institutionen for kemi och biomedicin, Suécia

Instituto Politécnico do Porto Instituto Superior de Engenharia do Porto, Portugal
European Union
Em curso
2019 - Atual Immunoprofiling characterisation of clinical samples by IHC and gene expression analysis and correlation with clinical outcomes in support of translational medicine strategies for ICOS and PD-L1-IC antibody therapeutics.
KYMAB_IPOPORTO_01
Other
2024/01 - 2027/12 PROSTAMET A Comprehensive Translational Research and Training Pipeline Harnessing Lipid Metabolism to Improve Prostate Cancer Management and Educate Young Researchers in Tackling Complex Disease
Co-Investigador Responsável (Co-IR)
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Marie Curie
2023/03/01 - 2026/02/28 On the crossroads of Immuno-Epigenetics for targeting advanced Prostate Cancer
2022.04809.PTDC
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2023/01/01 - 2025/12/31 Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors
TRANSCAN3/0001/2021
Investigador responsável
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2021/01/01 - 2025/12/31 Health Research Network: From Lab to Community Health
LA/P/0053/2020
Universidade do Porto Faculdade de Medicina, Portugal

Centro de Investigação em Tecnologias e Serviços de Saúde, Portugal

Universidade do Porto Unidade de Investigação e Desenvolvimento Cardiovascular, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Universidade NOVA de Lisboa, Portugal

Escola Superior de Enfermagem do Porto, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Universidade de Aveiro, Portugal

Universidade da Madeira, Portugal

Universidade do Algarve, Portugal

Associação para a Investigação e Desenvolvimento da Faculdade de Medicina, Portugal

Universidade de Lisboa Centro Cardiovascular da Universidade de Lisboa, Portugal

Universidade do Porto Faculdade de Ciências, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2022/01/01 - 2024/12/31 GLYCOTARGET. A NEW FRONTIER IN EXTRACELLULAR VESICLE-MEDIATED CANCER IMMUNOMODULATION
PTDC/MEC-ONC/0491/2021
Investigador
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto de Astrofísica e Ciências do Espaço, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2020/01 - 2024/12 Research Center of Portuguese Oncology Institute of Porto - Programatic Funding
UIDP/00776/2020
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2020/01 - 2024/12 Research Center of Portuguese Oncology Institute of Porto - Base Funding
UIDB/00776/2020
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2021/12/01 - 2024/11/30 diffNET - Restoring differentiation in cancer cells by manipulating RNA-binding protein NETworks
PTDC/BIA-CEL/0456/2021
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Fundação Champalimaud, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2023/03/12 - 2024/09/11 Decoding the role of extracellular vesicles in prostate cancer bone metastasis
2022.05135.PTDC
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Fundação Champalimaud, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2021/03/01 - 2024/02/29 CyclicCell - Cyclic loading effects in bladder cancer cells
PTDC/EME-APL/1342/2020
Co-Investigador Responsável (Co-IR)
Instituto de Ciência e Inovação em Engenharia Mecânica e Engenharia, Portugal

Associated Laboratory for Energy Transports and Aeronautics, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2021/06/01 - 2023/11/30 The Porto Comprehensive Cancer Center
PINFRA03/72678/2020
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Universidade do Porto Instituto de Biologia Molecular e Celular, Portugal

Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal

Instituto Nacional de Engenharia Biomédica, Portugal

Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2022/01/17 - 2023/07/16 Bridging iRon metabolism and immunE cells at the irrAdiateD tumOUr microenvironmenT to identify novel therapeutic targets in rectal cancer
EXPL/BIA-CEL/1225/2021
Investigador
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2016/01 - 2022/12 Assessment and validation of a panel of methylation-based Biomarkers in cell free DNA for Detection of recurrent first primary cancer (RFPC) and second primary cancers (SPC)
(CI-IPOP-74-2016)
Investigador responsável
Research Centre of Portuguese Oncology Institute
2018/08/10 - 2021/12/31 ACCuseD renAl Cell Carcinoma Detection Renal Cancer detection: a translational metabolomics research based on Volatile Organic Compounds fingerprinting
PTDC/SAU-SER/30388/2017
Rede de Química e Tecnologia Laboratório Associado para a Química Verde, Portugal

Fundação Ensino e Cultura Fernando Pessoa, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Associação para a Inovação e Desenvolvimento da FCT, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2018/01 - 2021/06/30 EpiMarkGermCell-DEVELOPMENT OF NOVEL PROGNOSTIC AND PREDICTIVE EPIGENETIC BIOMARKERS FOR MALIGNANT TESTICULAR GERM CELL TUMORS
POCI-01-0145-FEDER-29043
PTDC/MEC-URO/29043/2017
Co-Investigador Responsável (Co-IR)
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2017 - 2020 ESTIMA: Early stage cancer treatment driven by context of molecular imaging
ESTIMA-NORTE-01-0145-FEDER-000027
Investigador
Fundo Regional para a Ciência e Tecnologia
2019/01/01 - 2019/12/31 Portuguese Oncology Institute - Porto Research Center
UID/DTP/00776/2019
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2017/09/20 - 2019/12/22 New natural and synthetic compounds for the treatment of hormone-resistant tumors
SAICT-POL/24156/2016
Co-Investigador Responsável (Co-IR)
Instituto Politécnico do Porto, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2015/01 - 2017/12 Epigenetic signature of prostate cancer stem cells
(CI-IPOP-17-2015)
Investigador
Research Centre of Portuguese Oncology Institute of Porto
2012/03/15 - 2015/07/14 Epigenetic regulation in mammary stem/progenitor cells and its contribution to malignant transformation
PTDC/SAU-ONC/118346/2010
Investigador responsável
Universidade de Aveiro, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

University of Houston, Estados Unidos

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Universidade de Aveiro Departamento de Ciências Médicas, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2013/04 - 2014/03 Discovery of novel microRNA genes epigenetically down-regulated in prostate cancer
EXPL/BIM-ONC/0556/2012
Investigador responsável
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Fundação para a Ciência e a Tecnologia, I.P.

Fundação para a Ciência e a Tecnologia
Concluído
2011/01/01 - 2013/12/31 Strategic Project - UI 776 - 2011-2012
PEst-OE/SAU/UI0776/2011
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2010/01 - 2013/12 Genomic and phenotypic impact of the combined use of epigenetic modulating drugs in prostate cancer
NA
Investigador responsável
Liga Portuguesa Contra o Cancro – Núcleo Regional do Norte (Portuguese League Against Cancer – North)
2010/01 - 2012/12 Project EpiDiaCan: Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer
FP7-241783
Investigador responsável
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
European Commission
2008/05 - 2010/04 Screening for urological neoplasias by new epigenetic biomarkers
96474
Investigador responsável
Fundação Calouste Gulbenkian
2002/10/01 - 2004/09/30 DETECTION OF NEOPLASTIC CELLS BY DNA-BASED TECHNOLOGY IN CLINICAL SAMPLES OBTAINED BY NONINVASIVE OR MINIMALLY INVASIVE METHODS
SFRH/BPD/8031/2002
Investigador responsável
Fundação para a Ciência e a Tecnologia
Concluído
1997/10/01 - 2001/09/30 GABBA PhD Program_Academic Year_MANDATORY MODULES: CELL BIOLOGY, DEVELOPMENTAL BIOLOGY, MOLECULAR BIOLOGY, BIOPATHOLOGY, FORMAL GENETICS IMMUNOLOGY, NEUROBIOLOGY, NEUROENDOCRINOLOGY, ONCOBIOLOGY
PRAXIS XXI/BD/13398/97
Fundação para a Ciência e a Tecnologia
Concluído
1996/10/01 - 1997/09/30 STUDY OF SOME BIOMOLECULAR PARAMETERS IN BLADDER NEOPLASMS - MASTERS IN ONCOLOGY
PRAXIS XXI/BM/8579/96
Fundação para a Ciência e a Tecnologia
Concluído
Produções

Publicações

Artigo em conferência
  1. Bárbara Matos; John Howl; Carmen Jerónimo; Margarida Fardilha. "CAVPENET Decreases Prostate Cancer Cells Proliferation and Invasion through Modulation of Protein Phosphatase Activity". 2023.
    10.3390/blsf2023021017
Artigo em revista
  1. Eduarda P. Martins; Joana Vieira de Castro; Rita Fontes; Sara Monteiro-Reis; Rui Henrique; Carmen Jerónimo; Bruno M. Costa. "Relevance of HOTAIR rs920778 and rs12826786 Genetic Variants in Bladder Cancer Risk and Survival". Cancers (2024): https://doi.org/10.3390/cancers16020434.
    10.3390/cancers16020434
  2. Mayayo-Peralta, Isabel; Debets, Donna O.; Prekovic, Stefan; Schuurman, Karianne; Beerthuijzen, Suzanne; Almekinders, Mathilde; Sanders, Joyce; et al. "Proteomics on malignant pleural effusions reveals ERalpha loss in metastatic breast cancer associates withSGK1/NDRG1 deregulation". Molecular Oncology 18 1 (2023): 156-169. http://dx.doi.org/10.1002/1878-0261.13540.
    10.1002/1878-0261.13540
  3. Catarina Macedo-Silva; Vera Miranda-Gonçalves; Nuno Tiago Tavares; Daniela Barros-Silva; Joana Lencart; João Lobo; Ângelo Oliveira; et al. "Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling". Signal Transduction and Targeted Therapy (2023): https://doi.org/10.1038/s41392-023-01639-6.
    10.1038/s41392-023-01639-6
  4. Vânia Camilo; Mariana Brütt Pacheco; Filipa Moreira-Silva; Gonçalo Outeiro-Pinho; Vítor M. Gaspar; João F. Mano; C. Joana Marques; Rui Henrique; Carmen Jerónimo. "Novel Insights on the Role of Epigenetics in Androgen Receptor’s Expression in Prostate Cancer". Biomolecules (2023): https://doi.org/10.3390/biom13101526.
    10.3390/biom13101526
  5. Sequeira, José Pedro; Barros-Silva, Daniela; Ferreira-Torre, Patrícia; Salta, Sofia; Braga, Isaac; Carvalho, João; Freitas, Rui; Henrique, Rui; Jerónimo, Carmen. "OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach". International Journal of Molecular Sciences 24 18 (2023): 13890. http://dx.doi.org/10.3390/ijms241813890.
    10.3390/ijms241813890
  6. Salta, Sofia; Lobo, João; Magalhães, Bruno; Henrique, Rui; Jerónimo, Carmen. Autor correspondente: Jerónimo, Carmen. "DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis". Clinical Epigenetics 15 1 (2023): http://dx.doi.org/10.1186/s13148-023-01537-2.
    Publicado • 10.1186/s13148-023-01537-2
  7. Nuno Tiago Tavares; Rui Henrique; Aditya Bagrodia; Carmen Jerónimo; João Lobo. "A stroll through the present and future of testicular germ cell tumour biomarkers". Expert Review of Molecular Diagnostics (2023): https://doi.org/10.1080/14737159.2023.2206956.
    10.1080/14737159.2023.2206956
  8. Daniela Barros-Silva; Johan Tsui; Carmen Jerónimo; Guido Jenster; Elena S Martens-Uzunova. "Site-specific analysis of ribosomal 2'O-methylation by quantitative reverse transcription PCR under low deoxynucleotide triphosphate concentrations". BioTechniques (2023): https://doi.org/10.2144/btn-2022-0122.
    10.2144/btn-2022-0122
  9. Lobo, João; Tavares, Nuno Tiago; Barros-Silva, Daniela; Rosinha, Alina; Morais, António; Jerónimo, Carmen; Rodrigues, Ângelo; Henrique, Rui. "MiR-371a-3p in cystic trophoblastic tumour of the testis: supporting a maturation phenomenon towards teratoma". Histopathology 83 1 (2023): 151-154. http://dx.doi.org/10.1111/his.14929.
    10.1111/his.14929
  10. dos Reis, FD; Jerónimo, Carmen; Correia, Margareta. Autor correspondente: Correia, Margareta. "Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity". Frontiers in Immunology (2023): https://www.frontiersin.org/articles/10.3389/fimmu.2023.1152572/full.
    Publicado • 10.3389/fimmu.2023.1152572
  11. Ana Teixeira-Marques; Catarina Lourenço; Miguel Carlos Oliveira; Rui Henrique; Carmen Jerónimo. "Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?". International Journal of Molecular Sciences (2023): https://doi.org/10.3390/ijms24076757.
    10.3390/ijms24076757
  12. Montezuma, Diana; Varelas, Ana Isabel; Leite-Silva, Pedro; Teixeira-Marques, Ana; Monteiro-Reis, Sara; Oliveira, Miguel Carlos; Carvalho, João André; et al. "Impact of Standard Clinicopathologic Parameters in a Contemporary Cohort of Bladder Urothelial Carcinoma With 10 Years of Follow-Up". Human Pathology (2023):
    Submetido
  13. Francisco Conceição; Daniela M. Sousa; Sofia Tojal; Catarina Lourenço; Carina Carvalho-Maia; Helena Estevão-Pereira; João Lobo; et al. "The Secretome of Parental and Bone Metastatic Breast Cancer Elicits Distinct Effects in Human Osteoclast Activity after Activation of ß2 Adrenergic Signaling". Biomolecules (2023): https://doi.org/10.3390/biom13040622.
    10.3390/biom13040622
  14. Tânia Lima; Catarina Macedo-Silva; Diana Felizardo; João Fraga; Isa Carneiro; Carmen Jerónimo; Rui Henrique; Margarida Fardilha; Rui Vitorino. "Gal-3 Protein Expression and Localization in Prostate Tumours". Current Oncology (2023): https://doi.org/10.3390/curroncol30030206.
    10.3390/curroncol30030206
  15. Nuno Tiago Tavares; Rui Henrique; Carmen Jerónimo; João Lobo. "Targeting histone deacetylases in testicular germ cell tumours: an encouraging treatment approach for the future†". The Journal of Pathology (2023): https://doi.org/10.1002/path.6037.
    10.1002/path.6037
  16. Jan Roška; João Lobo; Danica Ivovic; Lenka Wachsmannová; Thomas Mueller; Rui Henrique; Carmen Jerónimo; Miroslav Chovanec; Dana Jurkovicová. "Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours". International Journal of Molecular Sciences (2023): https://doi.org/10.3390/ijms24032495.
    10.3390/ijms24032495
  17. Macedo-Silva, Catarina; Constâncio, Vera; Miranda-Gonçalves, Vera; Leite-Silva, Pedro; Salta, Sofia; Lobo, João; Guimarães, Rita; et al. "DNA methylation biomarkers accurately detect esophageal cancer prior and post neoadjuvant chemoradiation". Cancer Medicine 12 7 (2023): 8777-8788. http://dx.doi.org/10.1002/cam4.5623.
    10.1002/cam4.5623
  18. Sara Monteiro-Reis; João P. S. Ferreira; Ricardo A. Pires; João Lobo; João A. Carvalho; Rui L. Reis; Renato Natal Jorge; Carmen Jerónimo. "Bladder Wall Stiffness after Cystectomy in Bladder Cancer Patients: A Preliminary Study". Cancers (2023): https://doi.org/10.3390/cancers15020359.
    10.3390/cancers15020359
  19. Monteiro-Reis, Sara; Miranda-Gonçalves, Vera; Guimarães-Teixeira, Catarina; Martins-Lima, Cláudia; Lobo, João; Montezuma, Diana; Dias, Paula C.; et al. "Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition". International Journal of Biological Sciences 19 1 (2023): 1-12. http://dx.doi.org/10.7150/ijbs.77181.
    Publicado • 10.7150/ijbs.77181
  20. Anabela Couto-Cunha; Carmen Jerónimo; Rui Henrique. "Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?". Cancers (2022): https://doi.org/10.3390/cancers15010287.
    10.3390/cancers15010287
  21. Inês Direito; Daniela Gomes; Fátima Liliana Monteiro; Isa Carneiro; João Lobo; Rui Henrique; Carmen Jerónimo; Luisa Alejandra Helguero. "The Clinicopathological Significance of BiP/GRP-78 in Breast Cancer: A Meta-Analysis of Public Datasets and Immunohistochemical Detection". Current Oncology (2022): https://doi.org/10.3390/curroncol29120710.
    10.3390/curroncol29120710
  22. Daniela M. Sousa; Veronica Fernandes; Catarina Lourenço; Carina Carvalho-Maia; Helena Estevão-Pereira; João Lobo; Mariana Cantante; et al. "Profiling the Adrenergic System in Breast Cancer and the Development of Metastasis". Cancers (2022): https://doi.org/10.3390/cancers14225518.
    10.3390/cancers14225518
  23. Outeiro-Pinho, Gonçalo; Barros-Silva, Daniela; Moreira-Silva, Filipa; Lobo, João; Carneiro, Isa; Morais, António; Martins, Eduarda P; et al. "Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness". Translational Research 249 (2022): 110-127. https://www.translationalres.com/article/S1931-5244(22)00141-4/fulltext.
    Publicado
  24. Vera Constâncio; Nuno Tiago Tavares; Rui Henrique; Carmen Jerónimo; João Lobo. "MiRNA biomarkers in cancers of the male reproductive system: Are we approaching clinical application?". Andrology (2022): https://doi.org/10.1111/andr.13258.
    10.1111/andr.13258
  25. Nuno Tiago Tavares; Saule Gumauskaite; João Lobo; Carmen Jerónimo; Rui Henrique. "DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?". Cancers 14 12 (2022): 2918-2918. https://doi.org/10.3390/cancers14122918.
    10.3390/cancers14122918
  26. Tânia Lima; António S. Barros; Fábio Trindade; Rita Ferreira; Adelino Leite-Moreira; Daniela Barros-Silva; Carmen Jerónimo; et al. "Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study". Cancers 14 8 (2022): 2001-2001. https://doi.org/10.3390/cancers14082001.
    10.3390/cancers14082001
  27. Catarina Lourenço; Francisco Conceição; Carmen Jeronimo; Carmen Jerónimo; Meriem Lamghari; Daniela M. Sousa. "Stress in Metastatic Breast Cancer: To the Bone and Beyond". Cancers (2022): https://www.mdpi.com/2072-6694/14/8/1881.
    10.3390/cancers14081881
  28. Beatriz Chaves Lourenço; Catarina Guimarães-Teixeira; Bianca C. T. Flores; Vera Miranda-Gonçalves; Rita Guimarães; Mariana Cantante; Paula Lopes; et al. "Ki67 and LSD1 Expression in Testicular Germ Cell Tumors Is Not Associated with Patient Outcome: Investigation Using a Digital Pathology Algorithm". Life (2022): https://doi.org/10.3390/life12020264.
    10.3390/life12020264
  29. José Pedro Sequeira; Vera Constâncio; Sofia Salta; João Lobo; Daniela Barros-Silva; Carina Carvalho-Maia; Jéssica Rodrigues; et al. "LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma". Cancers (2022): https://doi.org/10.3390/cancers14040858.
    10.3390/cancers14040858
  30. Sara Petronilho; José Pedro Sequeira; Sofia Paulino; Paula Lopes; Susana Lisboa; Sérgio Chacim; João Lobo; et al. "Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma". Journal of Personalized Medicine (2021): https://doi.org/10.3390/jpm11121384.
    10.3390/jpm11121384
  31. João Lobo; Vera Constâncio; Pedro Leite-Silva; Rita Guimarães; Mariana Cantante; Isaac Braga; Joaquina Maurício; et al. "Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples". Clinical Epigenetics (2021): https://doi.org/10.1186/s13148-021-01048-y.
    10.1186/s13148-021-01048-y
  32. Catarina Macedo-Silva; Rosaria Benedetti; Fortunato Ciardiello; Salvatore Cappabianca; Carmen Jerónimo; Lucia Altucci. "Epigenetic mechanisms underlying prostate cancer radioresistance". Clinical Epigenetics (2021): https://doi.org/10.1186/s13148-021-01111-8.
    10.1186/s13148-021-01111-8
  33. Juliana Pedro; Sara Monteiro-Reis; Carina Carvalho-Maia; Rui Henrique; Carmen Jerónimo; Eunice R. Silva. "Evidence of psychological and biological effects of structured Mindfulness-Based Interventions for cancer patients and survivors: A meta-review". Psycho-Oncology 30 11 (2021): 1836-1848. https://doi.org/10.1002/pon.5771.
    10.1002/pon.5771
  34. Sandra M. Rocha; Inês Sousa; Inês M. Gomes; Patrícia Arinto; Pedro Costa-Pinheiro; Eduarda Coutinho; Cecília R. Santos; et al. "Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis". Life 11 11 (2021): 1251-1251. https://doi.org/10.3390/life11111251.
    10.3390/life11111251
  35. João Lobo; Carmen Jerónimo; Rui Henrique. "Morphological and molecular heterogeneity in testicular germ cell tumors: implications for dedicated investigations". Virchows Archiv (2021): https://doi.org/10.1007/s00428-021-03194-3.
    10.1007/s00428-021-03194-3
  36. José Pedro Sequeira; Vera Constâncio; João Lobo; Rui Henrique; Carmen Jerónimo. "Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma". Cancers 13 21 (2021): 5252-5252. https://doi.org/10.3390/cancers13215252.
    10.3390/cancers13215252
  37. Daniela Barros-Silva; Jonathan Klavert; Guido Jenster; Carmen Jerónimo; Denis L.J. Lafontaine; Elena S. Martens-Uzunova. "The role of OncoSnoRNAs and Ribosomal RNA 2'-O-methylation in Cancer". RNA Biology 18 sup1 (2021): 61-74. https://doi.org/10.1080/15476286.2021.1991167.
    10.1080/15476286.2021.1991167
  38. Diana Montezuma; Ana Teixeira-Marques; Carmen Jerónimo; Rui Henrique. "Epigenetic extracellular vesicle-based biomarkers for urological malignancies: is the hope worth the hype?". Epigenomics 13 19 (2021): 1514-1521. https://doi.org/10.2217/epi-2021-0333.
    10.2217/epi-2021-0333
  39. Catarina Guimarães-Teixeira; Daniela Barros Silva; João Lobo; Diana Soares-Fernandes; Vera Constâncio; Pedro Leite-Silva; Rui Silva-Santos; et al. "Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes". Journal of Personalized Medicine (2021): https://www.mdpi.com/2075-4426/11/10/996.
    10.3390/jpm11100996
  40. Bianca C. T. Flores; Margareta P. Correia; José G. Rodríguez; Rui Henrique; Carmen Jerónimo. "Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer". Cancers (2021): https://doi.org/10.3390/cancers13164209.
    10.3390/cancers13164209
  41. Nair Lopes; Mariana Brütt Pacheco; Diana Soares-Fernandes; Margareta P. Correia; Vânia Camilo; Rui Henrique; Carmen Jerónimo. "Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer". Biomedicines 9 8 (2021): 976-976. https://doi.org/10.3390/biomedicines9080976.
    10.3390/biomedicines9080976
  42. Mariana Brütt Pacheco; Vânia Camilo; Nair Lopes; Filipa Moreira-Silva; Margareta P. Correia; Rui Henrique; Carmen Jerónimo. "Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines". Pharmaceuticals 14 7 (2021): 670-670. https://doi.org/10.3390/ph14070670.
    10.3390/ph14070670
  43. Diana Gulei; Alice Indini; Carmen Jerónimo; Cristina-Adela Iuga; Francesco Grossi. "Cancer Mechanisms and Emerging Therapies". Pharmaceutics 13 7 (2021): 1045-1045. https://doi.org/10.3390/pharmaceutics13071045.
    10.3390/pharmaceutics13071045
  44. Inês Direito; Liliana Monteiro; Tânia Melo; Daniela Figueira; João Lobo; Vera Enes; Gabriela Moura; et al. "Protein Aggregation Patterns Inform about Breast Cancer Response to Antiestrogens and Reveal the RNA Ligase RTCB as Mediator of Acquired Tamoxifen Resistance". Cancers 13 13 (2021): 3195-3195. https://doi.org/10.3390/cancers13133195.
    10.3390/cancers13133195
  45. Mariana Brütt Pacheco; Vânia Camilo; Rui Henrique; Carmen Jerónimo. "Epigenetic Editing in Prostate Cancer: Challenges and Opportunities". Epigenetics (2021): https://doi.org/10.1080/15592294.2021.1939477.
    10.1080/15592294.2021.1939477
  46. Anna Adam-Artigues; Iris Garrido-Cano; J.A. Carbonell-Asins; Ana Lameirinhas; Soraya Simón; Belén Ortega-Morillo; María Teresa Martínez; et al. "Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer". Cancers (2021): https://www.mdpi.com/2072-6694/13/11/2848.
    10.3390/cancers13112848
  47. Ângela Carvalho; Gabriela Ferreira; Duarte Seixas; Catarina Guimarães-Teixeira; Rui Henrique; Fernando J. Monteiro; Carmen Jerónimo. "Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation". Cancers (2021): https://doi.org/10.3390/cancers13092101.
    10.3390/cancers13092101
  48. Catarina Lourenço; Vera Constâncio; Rui Henrique; Ângela Carvalho; Carmen Jerónimo. "Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances". Cancers 13 7 (2021): 1529-1529. https://doi.org/10.3390/cancers13071529.
    10.3390/cancers13071529
  49. Joana Pinto; Ângela Carapito; Filipa Amaro; Ana Rita Lima; Carina Carvalho-Maia; Maria Conceição Martins; Carmen Jerónimo; et al. "Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics". Metabolites 11 4 (2021): 199-199. https://doi.org/10.3390/metabo11040199.
    10.3390/metabo11040199
  50. Sara Monteiro-Reis; Carina Carvalho-Maia; Genevieve Bart; Seppo J. Vainio; Juliana Pedro; Eunice R. Silva; Goreti Sales; Rui Henrique; Carmen Jerónimo. "Secreted Extracellular Vesicle Molecular Cargo as a Novel Liquid Biopsy Diagnostics of Central Nervous System Diseases". International Journal of Molecular Sciences (2021): https://doi.org/10.3390/ijms22063267.
    10.3390/ijms22063267
  51. João Lobo; Ricardo Leão; Carmen Jerónimo; Rui Henrique. "Liquid Biopsies in the Clinical Management of Germ Cell Tumor Patients: State-of-the-Art and Future Directions". International Journal of Molecular Sciences 22 5 (2021): 2654-2654. https://doi.org/10.3390/ijms22052654.
    10.3390/ijms22052654
  52. João Lobo; Ana Rita Cardoso; Vera Miranda-Gonçalves; Leendert H. J. Looijenga; Marie Lopez; Paola B. Arimondo; Rui Henrique; Carmen Jerónimo. "Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest". Pharmaceutics (2021): https://doi.org/10.3390/pharmaceutics13010073.
    10.3390/pharmaceutics13010073
  53. Filipa Quintela Vieira; Ângela Marques-Magalhães; Vera Miranda-Gonçalves; Ricardo Ferraz; Mónica Vieira; Cristina Prudêncio; Carmen Jerónimo; Regina Augusta Silva. "The Impact of [C16Pyr][Amp] on the Aggressiveness in Breast and Prostate Cancer Cell Lines". International Journal of Molecular Sciences 21 24 (2020): 9584-9584. https://doi.org/10.3390/ijms21249584.
    10.3390/ijms21249584
  54. Macedo-Silva, Catarina; Miranda-Gonçalves, Vera; Lameirinhas, Ana; Lencart, Joana; Pereira, Alexandre; Lobo, João; Guimarães, Rita; et al. "JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma". Cell Death & Disease 11 12 (2020): http://dx.doi.org/10.1038/s41419-020-03279-y.
    10.1038/s41419-020-03279-y
  55. Mário Fontes-Sousa; João Lobo; Silvana Lobo; Sofia Salta; Maria Amorim; Paula Lopes; Luís Antunes; et al. "Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence". Molecular Medicine 26 1 (2020): https://doi.org/10.1186/s10020-020-0147-5.
    10.1186/s10020-020-0147-5
  56. João Lobo; Sara Monteiro-Reis; Catarina Guimarães-Teixeira; Paula Lopes; Isa Carneiro; Carmen Jerónimo; Rui Henrique. "Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression". Journal of Translational Medicine (2020): https://doi.org/10.1186/s12967-020-02475-w.
    10.1186/s12967-020-02475-w
  57. Rita Silva-Oliveira; Filipa Ferreira Pereira; Sara Petronilho; Ana Teresa Martins; Ana Lameirinhas; Vera Constâncio; Inês Ribeiro; et al. "Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer". Journal of Clinical Medicine (2020): https://www.mdpi.com/2077-0383/9/12/3911.
    10.3390/jcm9123911
  58. Manuela Costantini; Carla Azzurra Amoreo; Liborio Torregrossa; Greta Alì; Enrico Munari; Carmen Jeronimo; Rui Henrique; et al. "Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication". Cancers 12 11 (2020): 3345-3345. https://doi.org/10.3390/cancers12113345.
    10.3390/cancers12113345
  59. Md Ismail Hosen; Nathalie Forey; Geoffroy Durand; Catherine Voegele; Selin Bilici; Patrice Hodonou Avogbe; Tiffany M. Delhomme; et al. "Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer". Cancers (2020): https://www.mdpi.com/2072-6694/12/12/3541.
    10.3390/cancers12123541
  60. Iris Garrido-Cano; Vera Constâncio; Anna Adam-Artigues; Ana Lameirinhas; Soraya Simón; Belen Ortega; María Teresa Martínez; et al. "Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer". International Journal of Molecular Sciences (2020): https://www.mdpi.com/1422-0067/21/19/7427.
    10.3390/ijms21197427
  61. João Lobo; Maria Ana Alzamora; Rita Guimarães; Mariana Cantante; Paula Lopes; Isaac Braga; Joaquina Maurício; Carmen Jerónimo; Rui Henrique. "p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome". Andrology 8 5 (2020): 1233-1242. https://doi.org/10.1111/andr.12814.
    10.1111/andr.12814
  62. João Lobo; Rita Guimarães; Vera Miranda-Gonçalves; Sara Monteiro-Reis; Mariana Cantante; Luís Antunes; Isaac Braga; et al. "Differential expression of DNA methyltransferases and demethylases among the various testicular germ cell tumor subtypes". Epigenomics (2020): https://doi.org/10.2217/epi-2020-0066.
    10.2217/epi-2020-0066
  63. Ana Rita Cardoso; João Lobo; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo. "Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of ‘epidrugs’". Epigenetics (2020): https://doi.org/10.1080/15592294.2020.1805682.
    10.1080/15592294.2020.1805682
  64. Sandra P. Nunes; Rui Henrique; Carmen Jerónimo; Jesús M. Paramio. "DNA Methylation as a Therapeutic Target for Bladder Cancer". Cells (2020): https://doi.org/10.3390/cells9081850.
    10.3390/cells9081850
  65. Gonçalo Outeiro-Pinho; Daniela Barros-Silva; Margareta P. Correia; Rui Henrique; Carmen Jerónimo. "Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs". Cancers 12 8 (2020): 2214-2214. https://doi.org/10.3390/cancers12082214.
    10.3390/cancers12082214
  66. Ana Rita Lima; Joana Pinto; Carina Carvalho-Maia; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho. "A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers". Cancers 12 8 (2020): 2017-2017. https://doi.org/10.3390/cancers12082017.
    10.3390/cancers12082017
  67. João Lobo; Carmen Jerónimo; Rui Henrique. "Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives". Cancers (2020): https://doi.org/10.3390/cancers12061601.
    10.3390/cancers12061601
  68. Ana Rita Lima; Joana Pinto; Daniela Barros-Silva; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes Pinho. "New findings on urinary prostate cancer metabolome through combined GC–MS and 1H NMR analytical platforms". Metabolomics 16 6 (2020): https://doi.org/10.1007/s11306-020-01691-1.
    10.1007/s11306-020-01691-1
  69. Nair Lopes; Margareta P. Correia; Rui Henrique; Carmen Jerónimo. "Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes". International Journal of Molecular Sciences 21 10 (2020): 3522-3522. https://doi.org/10.3390/ijms21103522.
    10.3390/ijms21103522
  70. Vera Miranda-Gonçalves; Ana Lameirinhas; Rui Henrique; Fátima Baltazar; Carmen Jerónimo. "The metabolic landscape of urological cancers: New therapeutic perspectives". Cancer Letters 477 (2020): 76-87. https://doi.org/10.1016/j.canlet.2020.02.034.
    10.1016/j.canlet.2020.02.034
  71. Filipa Moreira-Silva; Vânia Camilo; Vítor Gaspar; João F. Mano; Rui Henrique; Carmen Jerónimo. "Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?". Pharmaceutics 12 5 (2020): 410-410. https://doi.org/10.3390/pharmaceutics12050410.
    10.3390/pharmaceutics12050410
  72. Filipa Amaro; Joana Pinto; Sílvia Rocha; Ana Margarida Araújo; Vera Miranda-Gonçalves; Carmen Jerónimo; Rui Henrique; et al. "Volatilomics Reveals Potential Biomarkers for Identification of Renal Cell Carcinoma: An In Vitro Approach". Metabolites 10 5 (2020): 174-174. https://doi.org/10.3390/metabo10050174.
    10.3390/metabo10050174
  73. Vera Miranda-Gonçalves; Ana Lameirinhas; Catarina Macedo-Silva; João Lobo; Paula C. Dias; Verónica Ferreira; Rui Henrique; Carmen Jerónimo. "Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation". Cells (2020): https://doi.org/10.3390/cells9041053.
    10.3390/cells9041053
  74. Saudade André; Sandra P. Nunes; Fernanda Silva; Rui Henrique; Ana Félix; Carmen Jerónimo. "Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer". International Journal of Molecular Sciences 21 8 (2020): 2715-2715. https://doi.org/10.3390/ijms21082715.
    10.3390/ijms21082715
  75. Jerónimo, Carmen. "The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.". Urologic oncology (2020): https://doi.org/10.1016/j.urolonc.2020.03.004.
    10.1016/j.urolonc.2020.03.004
  76. Jerónimo, Carmen. "RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer.". Journal of clinical medicine (2020): https://doi.org/10.3390/jcm9041000.
    10.3390/jcm9041000
  77. Sara Monteiro-Reis; Ana Lameirinhas; Vera Miranda-Gonçalves; Diana Montezuma; Paula C. Dias; Jorge Oliveira; Inês Graça; et al. "Sirtuins’ Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion". Cancers (2020): https://www.mdpi.com/2072-6694/12/5/1066.
    10.3390/cancers12051066
  78. Daniela Barros-Silva; João Lobo; Catarina Guimarães-Teixeira; Isa Carneiro; Jorge Oliveira; Elena S. Martens-Uzunova; Rui Henrique; Carmen Jerónimo. "VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer". Cancers 12 4 (2020): 771-771. https://doi.org/10.3390/cancers12040771.
    10.3390/cancers12040771
  79. Vera Constâncio; Sandra P. Nunes; Rui Henrique; Carmen Jerónimo. "DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types". Cells (2020): https://doi.org/10.3390/cells9030624.
    10.3390/cells9030624
  80. Sara Monteiro-Reis; Ana Blanca; Joana Tedim-Moreira; Isa Carneiro; Diana Montezuma; Paula Monteiro; Jorge Oliveira; et al. "A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions". Journal of Clinical Medicine (2020): https://www.mdpi.com/2077-0383/9/2/605.
    10.3390/jcm9020605
  81. João Lobo; Carmen Jerónimo; Rui Henrique. "Targeting the Immune system and Epigenetic Landscape of Urological Tumors". International Journal of Molecular Sciences 21 3 (2020): 829-829. https://doi.org/10.3390/ijms21030829.
    10.3390/ijms21030829
  82. Jerónimo, Carmen. "Overexpression of circulating MiR-30b-5p identifies advanced breast cancer.". Journal of translational medicine (2019): https://europepmc.org/articles/PMC6936051.
    10.1186/s12967-019-02193-y
  83. João Lobo; Ad J.M. Gillis; Annette van den Berg; Lambert C.J. Dorssers; Gazanfer Belge; Klaus-Peter Dieckmann; Henk P. Roest; et al. "Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data". Cells (2019): https://www.mdpi.com/2073-4409/8/12/1637.
    10.3390/cells8121637
  84. Catarina Macedo-Silva; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo; Isabel Bravo. "The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance". Genes 10 11 (2019): 927-927. https://doi.org/10.3390/genes10110927.
    10.3390/genes10110927
  85. João Lobo; Carla Pinto; Manuela Pinheiro; Francisco Lobo; Nuno Sousa; Paula Lopes; Leendert HJ Looijenga; et al. "Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss". Histopathology (2019): https://doi.org/10.1111/his.13979.
    10.1111/his.13979
  86. João Lobo; Ângelo Rodrigues; Rita Guimarães; Mariana Cantante; Paula Lopes; Joaquina Maurício; Jorge Oliveira; Carmen Jerónimo; Rui Henrique. "Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers". Cancers (2019): https://doi.org/10.3390/cancers11101535.
    10.3390/cancers11101535
  87. Ana Rita Lima; Joana Pinto; Ana Isabel Azevedo; Daniela Barros-Silva; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Paula Guedes de Pinho; Márcia Carvalho. "Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine". British Journal of Cancer (2019): https://doi.org/10.1038/s41416-019-0585-4.
    10.1038/s41416-019-0585-4
  88. Vera Constâncio; Daniela Barros-Silva; Carmen Jerónimo; Rui Henrique. "Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies". Expert Review of Molecular Diagnostics (2019): 1-9. https://doi.org/10.1080/14737159.2019.1604224.
    10.1080/14737159.2019.1604224
  89. Ana Lameirinhas; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo. "The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma". Genes (2019): https://doi.org/10.3390/genes10040264.
    10.3390/genes10040264
  90. Sara Monteiro-Reis; João Lobo; Rui Henrique; Carmen Jerónimo. "Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer". International Journal of Molecular Sciences 20 2 (2019): 297-297. https://doi.org/10.3390/ijms20020297.
    10.3390/ijms20020297
  91. João Lobo; Ad J. M. Gillis; Carmen Jeronimo; Rui Henrique; Leendert Looijenga. "Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic". International Journal of Molecular Sciences (2019): http://www.mdpi.com/1422-0067/20/2/258.
    10.3390/ijms20020258
  92. Daniela Rodrigues; Joana Pinto; Ana Margarida Araújo; Carmen Jeronimo; Rui Henrique; Maria de Lourdes Bastos; Guedes de Pinho P.; Carvalho M. "GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells". Metabolites (2019): http://www.mdpi.com/2218-1989/9/1/18.
    10.3390/metabo9010018
  93. Ganesan, A.; Arimondo, P.B.; Rots, M.G.; Jeronimo, C.; Berdasco, M.. "The timeline of epigenetic drug discovery: From reality to dreams". Clinical Epigenetics 11 1 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85076064024&partnerID=MN8TOARS.
    10.1186/s13148-019-0776-0
  94. Avogbe, P.H.; Manel, A.; Vian, E.; Durand, G.; Forey, N.; Voegele, C.; Zvereva, M.; et al. "Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer". EBioMedicine 44 (2019): 431-438. http://www.scopus.com/inward/record.url?eid=2-s2.0-85067818432&partnerID=MN8TOARS.
    10.1016/j.ebiom.2019.05.004
  95. Amorim, M.; Lobo, J.; Fontes-Sousa, M.; Estevão-Pereira, H.; Salta, S.; Lopes, P.; Coimbra, N.; et al. "Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer". Frontiers in Genetics 10 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85072836043&partnerID=MN8TOARS.
    10.3389/fgene.2019.00815
  96. Lobo, J.; Costa, A.L.; Cantante, M.; Guimarães, R.; Lopes, P.; Antunes, L.; Braga, I.; et al. "M6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: A role in seminoma phenotype maintenance". Journal of Translational Medicine 17 1 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85062892627&partnerID=MN8TOARS.
    10.1186/s12967-019-1837-z
  97. Fontes-Sousa, M.; Amorim, M.; Salta, S.; De Sousa, S.P.; Henrique, R.; Jerónimo, C.. "Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review)". Oncology Reports 41 3 (2019): 1431-1438. http://www.scopus.com/inward/record.url?eid=2-s2.0-85060810377&partnerID=MN8TOARS.
    10.3892/or.2019.6967
  98. Carneiro, I.; Quintela-Vieira, F.; Lobo, J.; Moreira-Barbosa, C.; Menezes, F.D.; Martins, A.T.; Oliveira, J.; et al. "Expression of EMT-related genes CAMK2N1 and WNT5A is increased in locally invasive and metastatic prostate cancer". Journal of Cancer 10 24 (2019): 5915-5925. http://www.scopus.com/inward/record.url?eid=2-s2.0-85075870270&partnerID=MN8TOARS.
    10.7150/jca.34564
  99. Constâncio, V.; Nunes, S.P.; Moreira-Barbosa, C.; Freitas, R.; Oliveira, J.; Pousa, I.; Soares, M.; et al. "Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel". Clinical Epigenetics 11 1 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85075909374&partnerID=MN8TOARS.
    10.1186/s13148-019-0779-x
  100. Bidarra, D.; Constâncio, V.; Barros-Silva, D.; Ramalho-Carvalho, J.; Moreira-Barbosa, C.; Antunes, L.; Maurício, J.; et al. "Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction". Frontiers in Oncology 9 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85073032098&partnerID=MN8TOARS.
    10.3389/fonc.2019.00900
  101. Lobo, J.; Nunes, S.P.; Gillis, A.J.M.; Barros-Silva, D.; Miranda-Gonçalves, V.; van den Berg, A.; Cantante, M.; et al. "XIST-promoter demethylation as tissue biomarker for testicular germ cell tumors and spermatogenesis quality". Cancers 11 9 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85073413264&partnerID=MN8TOARS.
    10.3390/cancers11091385
  102. Vieira-Silva, T.S.; Monteiro-Reis, S.; Barros-Silva, D.; Ramalho-Carvalho, J.; Graça, I.; Carneiro, I.; Martins, A.T.; et al. "Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype". Cancer Cell International 19 1 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85065238373&partnerID=MN8TOARS.
    10.1186/s12935-019-0835-9
  103. Henrique, R.; Nunes, S.P.; Jerónimo, C.. "MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges". European Urology 75 2 (2019): 251-252. http://www.scopus.com/inward/record.url?eid=2-s2.0-85056732877&partnerID=MN8TOARS.
    10.1016/j.eururo.2018.11.014
  104. Antunes, J.; Gaspar, V.M.; Ferreira, L.; Monteiro, M.; Henrique, R.; Jerónimo, C.; Mano, J.F.. "In-air production of 3D co-culture tumor spheroid hydrogels for expedited drug screening". Acta Biomaterialia 94 (2019): 392-409. http://www.scopus.com/inward/record.url?eid=2-s2.0-85067296733&partnerID=MN8TOARS.
    10.1016/j.actbio.2019.06.012
  105. João Lobo; Rui Henrique; Carmen Jerónimo. "The Role of DNA/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors". Cancers (2018): https://doi.org/10.3390/cancers11010006.
    10.3390/cancers11010006
  106. Catarina Moreira-Barbosa; Daniela Barros-Silva; Pedro Costa-Pinheiro; Jorge Torres-Ferreira; Vera Constâncio; Rui Freitas; Jorge Oliveira; et al. "Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients". Clinical Epigenetics (2018): https://doi.org/10.1186/s13148-018-0564-2.
    10.1186/s13148-018-0564-2
  107. Ana Rita Lima; Ana Margarida Araújo; Joana Pinto; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho. "Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS". Scientific Reports 8 1 (2018): https://doi.org/10.1038/s41598-018-23847-9.
    10.1038/s41598-018-23847-9
  108. João Lobo; Daniela Barros-Silva; Rui Henrique; Carmen Jerónimo. "The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors". Genes 9 11 (2018): 552-552. https://doi.org/10.3390/genes9110552.
    10.3390/genes9110552
  109. Sofia Salta; Sandra Nunes; Mário Fontes-Sousa; Paula Lopes; Micaela Freitas; Margarida Caldas; Luís Antunes; et al. "A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA". Journal of Clinical Medicine (2018): http://www.mdpi.com/2077-0383/7/11/420.
    10.3390/jcm7110420
  110. Sandra Nunes; Catarina Moreira-Barbosa; Sofia Salta; Susana Palma de Sousa; Inês Pousa; Júlio Oliveira; Marta Soares; et al. "Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women". Cancers (2018): http://www.mdpi.com/2072-6694/10/10/357.
    10.3390/cancers10100357
  111. Daniela Barros Silva; C. Joana Marques; Rui Henrique; Carmen Jeronimo. "Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications". Genes (2018): http://www.mdpi.com/2073-4425/9/9/429.
    10.3390/genes9090429
  112. Lobo, J.; Rodrigues, Â.; Antunes, L.; Graça, I.; Ramalho-Carvalho, J.; Vieira, F.Q.; Martins, A.T.; et al. "High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer". Urologic Oncology: Seminars and Original Investigations 36 4 (2018): 161.e7-161.e17. http://www.scopus.com/inward/record.url?eid=2-s2.0-85034767173&partnerID=MN8TOARS.
    10.1016/j.urolonc.2017.10.028
  113. Oliveira, A.I.; Xavier-Magalhães, A.; Moreira-Barbosa, C.; Magalhães, H.; Henrique, R.; Jerónimo, C.; Costa, B.M.. "Influence of HOTAIR rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival". Biomarkers in Medicine 12 3 (2018): 257-264. http://www.scopus.com/inward/record.url?eid=2-s2.0-85044275664&partnerID=MN8TOARS.
    10.2217/bmm-2017-0258
  114. Lima, A.R.; Araújo, A.M.; Pinto, J.; Jerónimo, C.; Henrique, R.; Bastos, M.L.; Carvalho, M.; De Pinho, P.G.. "GC-MS-based endometabolome analysis differentiates prostate cancer from normal prostate cells". Metabolites 8 1 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85044334767&partnerID=MN8TOARS.
    10.3390/metabo8010023
  115. Marques-Magalhães, Â.; Graça, I.; Henrique, R.; Jerónimo, C.. "Targeting DNA methyltranferases in urological tumors". Frontiers in Pharmacology 9 APR (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85045512956&partnerID=MN8TOARS.
    10.3389/fphar.2018.00366
  116. Freitas, M.; Ferreira, F.; Carvalho, S.; Silva, F.; Lopes, P.; Antunes, L.; Salta, S.; et al. "A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway". Journal of Translational Medicine 16 1 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85042556578&partnerID=MN8TOARS.
    10.1186/s12967-018-1415-9
  117. Barros-Silva, D.; Costa-Pinheiro, P.; Duarte, H.; Sousa, E.J.; Evangelista, A.F.; Graça, I.; Carneiro, I.; et al. "MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis". Cell Death and Disease 9 2 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85041668396&partnerID=MN8TOARS.
    10.1038/s41419-017-0241-y
  118. Ramalho-Carvalho, J.; Gonçalves, C.S.; Graça, I.; Bidarra, D.; Pereira-Silva, E.; Salta, S.; Godinho, M.I.; et al. "A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97". Clinical Epigenetics 10 1 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85044357371&partnerID=MN8TOARS.
    10.1186/s13148-018-0475-2
  119. Jantsch, M.F.; Quattrone, A.; O'Connell, M.; Helm, M.; Frye, M.; Macias-Gonzales, M.; Ohman, M.; et al. "Positioning Europe for the EPITRANSCRIPTOMICS challenge". RNA Biology 15 6 (2018): 829-831. http://www.scopus.com/inward/record.url?eid=2-s2.0-85046696156&partnerID=MN8TOARS.
    10.1080/15476286.2018.1460996
  120. Vilela-Salgueiro, B.; Barros-Silva, D.; Lobo, J.; Costa, A.L.; Guimarães, R.; Cantante, M.; Lopes, P.; et al. "Germ cell tumour subtypes display differential expression of microRNA371a-3p". Philosophical Transactions of the Royal Society B: Biological Sciences 373 1748 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85045938699&partnerID=MN8TOARS.
    10.1098/rstb.2017.0338
  121. Lobo, J.; Costa, A.L.; Vilela-Salgueiro, B.; Rodrigues, Â.; Guimarães, R.; Cantante, M.; Lopes, P.; et al. "Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists". Human Pathology 82 (2018): 113-124. http://www.scopus.com/inward/record.url?eid=2-s2.0-85055478187&partnerID=MN8TOARS.
    10.1016/j.humpath.2018.07.016
  122. Pires-Luis, A.; Montezuma, D.; Vieira, J.; Ramalho-Carvalho, J.; Santos, C.; Teixeira, M.; Jerónimo, C.; Henrique, R.. "Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case". Experimental and Molecular Pathology 105 3 (2018): 352-356. http://www.scopus.com/inward/record.url?eid=2-s2.0-85055521380&partnerID=MN8TOARS.
    10.1016/j.yexmp.2018.10.008
  123. Ferreira, C.; Lobo, J.; Antunes, L.; Lopes, P.; Jerónimo, C.; Henrique, R.. "Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features". Virchows Archiv 473 4 (2018): 443-452. http://www.scopus.com/inward/record.url?eid=2-s2.0-85049849501&partnerID=MN8TOARS.
    10.1007/s00428-018-2406-1
  124. Rodrigues, D.; Pinto, J.; Araújo, A.M.; Monteiro-Reis, S.; Jerónimo, C.; Henrique, R.; de Lourdes Bastos, M.; de Pinho, P.G.; Carvalho, M.. "Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography–mass spectrometry". Metabolomics 14 5 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85045689037&partnerID=MN8TOARS.
    10.1007/s11306-018-1361-9
  125. Stelloo, S.; Nevedomskaya, E.; Kim, Y.; Schuurman, K.; Valle-Encinas, E.; Lobo, J.; Krijgsman, O.; et al. "Integrative epigenetic taxonomy of primary prostate cancer". Nature Communications 9 1 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85056980438&partnerID=MN8TOARS.
    10.1038/s41467-018-07270-2
  126. Carvalho, S.; Freitas, M.; Antunes, L.; Monteiro-Reis, S.; Vieira-Coimbra, M.; Tavares, A.; Paulino, S.; et al. "Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer". Journal of Cancer Research and Clinical Oncology 144 11 (2018): 2127-2137. http://www.scopus.com/inward/record.url?eid=2-s2.0-85051414323&partnerID=MN8TOARS.
    10.1007/s00432-018-2733-2
  127. Miranda-Gonçalves, V.; Lameirinhas, A.; Henrique, R.; Jerónimo, C.. "Metabolism and epigenetic interplay in cancer: Regulation and putative therapeutic targets". Frontiers in Genetics 9 OCT (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85055323422&partnerID=MN8TOARS.
    10.3389/fgene.2018.00427
  128. Schrijver, W.; Schuurman, K.; van Rossum, A.; Droog, M.; Jeronimo, C.; Salta, S.; Henrique, R.; et al. "FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome". Molecular Oncology 12 11 (2018): 1884-1894. http://www.scopus.com/inward/record.url?eid=2-s2.0-85054902906&partnerID=MN8TOARS.
    10.1002/1878-0261.12353
  129. Costa, A.L.; Moreira-Barbosa, C.; Lobo, J.; Vilela-Salgueiro, B.; Cantante, M.; Guimarães, R.; Lopes, P.; et al. "DNA methylation profiling as a tool for testicular germ cell tumors subtyping". Epigenomics 10 12 (2018): 1511-1523. http://www.scopus.com/inward/record.url?eid=2-s2.0-85058067353&partnerID=MN8TOARS.
    10.2217/epi-2018-0034
  130. Oriana Rainho Brás; Jean-Philippe Cointet; Alberto Cambrosio; Leonor David; João Arriscado Nunes; Fátima Cardoso; Carmen Jerónimo. "Oncology research in late twentieth century and turn of the century Portugal: a scientometric approach to its institutional and semantic dimensions". Scientometrics (2017): https://doi.org/10.1007/s11192-017-2491-y.
    10.1007/s11192-017-2491-y
  131. Bartosch, C.; Lopes, J.M.; Jerónimo, C.. "Epigenetics in endometrial carcinogenesis - Part 1: DNA methylation". Epigenomics 9 5 (2017): 737-755. http://www.scopus.com/inward/record.url?eid=2-s2.0-85019546735&partnerID=MN8TOARS.
    10.2217/epi-2016-0166
  132. Lobo, J.; Pinto, C.; Freitas, M.; Pinheiro, M.; Vizcaino, R.; Oliva, E.; Teixeira, M.R.; Jerónimo, C.; Bartosch, C.. "Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?". Virchows Archiv 470 3 (2017): 347-352. http://www.scopus.com/inward/record.url?eid=2-s2.0-85000893294&partnerID=MN8TOARS.
    10.1007/s00428-016-2052-4
  133. Ramalho-Carvalho, J.; Graça, I.; Gomez, A.; Oliveira, J.; Henrique, R.; Esteller, M.; Jerónimo, C.. "Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer". Journal of Hematology and Oncology 10 1 (2017): 1-13. http://www.scopus.com/inward/record.url?eid=2-s2.0-85011628776&partnerID=MN8TOARS.
    10.1186/s13045-017-0415-1
  134. Bartosch, C.; Lopes, J.M.; Jerónimo, C.. "Epigenetics in endometrial carcinogenesis - Part 2: Histone modifications, chromatin remodeling and noncoding RNAs". Epigenomics 9 6 (2017): 873-892. http://www.scopus.com/inward/record.url?eid=2-s2.0-85020775388&partnerID=MN8TOARS.
    10.2217/epi-2016-0167
  135. Bartosch, C.; Pires, M.; Jerónimo, C.; Lopes, J.M.. "The role of pathology in the management of patients with endometrial carcinoma". Future Oncology 13 11 (2017): 1003-1020. http://www.scopus.com/inward/record.url?eid=2-s2.0-85019097043&partnerID=MN8TOARS.
    10.2217/fon-2016-0570
  136. Monteiro, M.; Moreira, N.; Pinto, J.; Pires-Luís, A.S.; Henrique, R.; Jerónimo, C.; Bastos, M.D.L.; et al. "GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients". Journal of Cellular and Molecular Medicine 21 9 (2017): 2092-2105. http://www.scopus.com/inward/record.url?eid=2-s2.0-85017341119&partnerID=MN8TOARS.
    10.1111/jcmm.13132
  137. Henrique, R.; Jerónimo, C.. "Testicular Germ Cell Tumors Go Epigenetics: Will miR-371a-3p Replace Classical Serum Biomarkers?". European Urology 71 2 (2017): 221-222. http://www.scopus.com/inward/record.url?eid=2-s2.0-84996629679&partnerID=MN8TOARS.
    10.1016/j.eururo.2016.08.013
  138. Cruz-Neves, S.; Ribeiro, N.; Graça, I.; Jerónimo, C.; Sousa, S.R.; Monteiro, F.J.. "Behavior of prostate cancer cells in a nanohydroxyapatite/collagen bone scaffold". Journal of Biomedical Materials Research - Part A 105 7 (2017): 2035-2046. http://www.scopus.com/inward/record.url?eid=2-s2.0-85019060258&partnerID=MN8TOARS.
    10.1002/jbm.a.36070
  139. Padrão, N.A.; Monteiro-Reis, S.; Torres-Ferreira, J.; Antunes, L.; Leça, L.; Montezuma, D.; Ramalho-Carvalho, J.; et al. "MicroRNA promoter methylation: A new tool for accurate detection of urothelial carcinoma". British Journal of Cancer 116 5 (2017): 634-639. http://www.scopus.com/inward/record.url?eid=2-s2.0-85009423912&partnerID=MN8TOARS.
    10.1038/bjc.2016.454
  140. Costa, A.L.; Lobo, J.; Jerónimo, C.; Henrique, R.. "The epigenetics of testicular germ cell tumors: Looking for novel disease biomarkers". Epigenomics 9 2 (2017): 155-169. http://www.scopus.com/inward/record.url?eid=2-s2.0-85010285174&partnerID=MN8TOARS.
    10.2217/epi-2016-0081
  141. Rodrigues, D.; Monteiro, M.; Jerónimo, C.; Henrique, R.; Belo, L.; Bastos, M.D.L.; Guedes de Pinho, P.; Carvalho, M.. "Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems". Translational Research 180 (2017): 1-11. http://www.scopus.com/inward/record.url?eid=2-s2.0-84994418166&partnerID=MN8TOARS.
    10.1016/j.trsl.2016.07.018
  142. Ramalho-Carvalho, J.; Martins, J.B.; Cekaite, L.; Sveen, A.; Torres-Ferreira, J.; Graça, I.; Costa-Pinheiro, P.; et al. "Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1". Cancer Letters 385 (2017): 150-159. http://www.scopus.com/inward/record.url?eid=2-s2.0-85002424684&partnerID=MN8TOARS.
    10.1016/j.canlet.2016.10.028
  143. Monteiro, F.L.; Vitorino, R.; Wang, J.; Cardoso, H.; Laranjeira, H.; Simões, J.; Caldas, M.; et al. "The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial–mesenchymal transition in mammary epithelial and in breast cancer cells". Cancer Letters 396 (2017): 42-52. http://www.scopus.com/inward/record.url?eid=2-s2.0-85015871656&partnerID=MN8TOARS.
    10.1016/j.canlet.2017.03.007
  144. Torres-Ferreira, J.; Ramalho-Carvalho, J.; Gomez, A.; Menezes, F.D.; Freitas, R.; Oliveira, J.; Antunes, L.; et al. "MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors". Molecular Cancer 16 1 (2017): http://www.scopus.com/inward/record.url?eid=2-s2.0-85011049864&partnerID=MN8TOARS.
    10.1186/s12943-017-0604-0
  145. Ferreira, L.P.; Gaspar, V.M.; Henrique, R.; Jerónimo, C.; Mano, J.F.. "Mesenchymal Stem Cells Relevance in Multicellular Bioengineered 3D In Vitro Tumor Models". Biotechnology Journal 12 12 (2017): http://www.scopus.com/inward/record.url?eid=2-s2.0-85038367857&partnerID=MN8TOARS.
    10.1002/biot.201700079
  146. Pires-Luís, A.S.; Costa-Pinheiro, P.; Ferreira, M.J.; Antunes, L.; Lobo, F.; Oliveira, J.; Henrique, R.; Jerónimo, C.. "Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel". Journal of Translational Medicine 15 1 (2017): http://www.scopus.com/inward/record.url?eid=2-s2.0-85021361205&partnerID=MN8TOARS.
    10.1186/s12967-017-1248-y
  147. Ferreira, M.J.; Pires-Luís, A.S.; Vieira-Coimbra, M.; Costa-Pinheiro, P.; Antunes, L.; Dias, P.C.; Lobo, F.; et al. "SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization". Epigenetics 12 12 (2017): 1057-1064. http://www.scopus.com/inward/record.url?eid=2-s2.0-85041099632&partnerID=MN8TOARS.
    10.1080/15592294.2017.1385685
  148. Bartosch, C.; Pires-Luís, A.S.; Meireles, C.; Baptista, M.; Gouveia, A.; Pinto, C.; Shannon, K.M.; et al. "Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients with Lynch Syndrome". American Journal of Surgical Pathology 40 9 (2016): 1177-1191. http://www.scopus.com/inward/record.url?eid=2-s2.0-84976330403&partnerID=MN8TOARS.
    10.1097/PAS.0000000000000684
  149. Amorim, M.; Salta, S.; Henrique, R.; Jer�nimo, C.. "Decoding the usefulness of non-coding RNAs as breast cancer markers". Journal of Translational Medicine 14 1 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-84987729451&partnerID=MN8TOARS.
    10.1186/s12967-016-1025-3
  150. Almeida-Rios, D.; Gra�a, I.; Vieira, F.Q.; Ramalho-Carvalho, J.; Pereira-Silva, E.; Martins, A.T.; Oliveira, J.; et al. "Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer". Oncotarget 7 33 (2016): 53018-53028. http://www.scopus.com/inward/record.url?eid=2-s2.0-84982255260&partnerID=MN8TOARS.
    10.18632/oncotarget.10061
  151. Ramalho-Carvalho, J.; Fromm, B.; Henrique, R.; Jerónimo, C.. "Deciphering the function of non-coding RNAs in prostate cancer". Cancer and Metastasis Reviews 35 2 (2016): 235-262. http://www.scopus.com/inward/record.url?eid=2-s2.0-84975883570&partnerID=MN8TOARS.
    10.1007/s10555-016-9628-y
  152. Gra�a, I.; Pereira-Silva, E.; Henrique, R.; Packham, G.; Crabb, S.J.; Jer�nimo, C.. "Epigenetic modulators as therapeutic targets in prostate cancer". Clinical Epigenetics 8 1 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-85043541626&partnerID=MN8TOARS.
    10.1186/s13148-016-0264-8
  153. Monteiro, M.S.; Barros, A.S.; Pinto, J.; Carvalho, M.; Pires-Luís, A.S.; Henrique, R.; Jerónimo, C.; et al. "Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma". Scientific Reports 6 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-84997079401&partnerID=MN8TOARS.
    10.1038/srep37275
  154. Bartosch, C.; Monteiro-Reis, S.; Almeida-Rios, D.; Vieira, R.; Castro, A.; Moutinho, M.; Rodrigues, M.; et al. "Assessing sirtuin expression in endometrial carcinoma and nonneoplastic endometrium". Oncotarget 7 2 (2016): 1144-1154. http://www.scopus.com/inward/record.url?eid=2-s2.0-84957642755&partnerID=MN8TOARS.
    10.18632/oncotarget.6691
  155. Jerónimo, C.; Henrique, R.. "Is There a Role for Exosome-derived MicroRNAs in Detection of Renal Cell Tumors Using Urine Samples? Editorial to [European Urology Focus 2/2 (2016) 210–218]". European Urology Focus 2 6 (2016): 654-655. http://www.scopus.com/inward/record.url?eid=2-s2.0-85017280411&partnerID=MN8TOARS.
    10.1016/j.euf.2016.01.001
  156. Ribeiro, N.; Costa-Pinheiro, P.; Henrique, R.; Gomez-Lazaro, M.; Pereira, M.P.; Mansur, A.A.P.; Mansur, H.S.; et al. "Comprehensive analysis of secreted protein, acidic and rich in cysteine in prostate carcinogenesis: Development of a 3d nanostructured bone-like model". Journal of Biomedical Nanotechnology 12 8 (2016): 1667-1678. http://www.scopus.com/inward/record.url?eid=2-s2.0-84986593214&partnerID=MN8TOARS.
    10.1166/jbn.2016.2276
  157. Luedeke, M.; Rinckleb, A.E.; FitzGerald, L.M.; Geybels, M.S.; Schleutker, J.; Eeles, R.A.; Teixeira, M.R.; et al. "Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2: ERG fusion status". Human Molecular Genetics 25 24 (2016): 5490-5499. http://www.scopus.com/inward/record.url?eid=2-s2.0-85016002209&partnerID=MN8TOARS.
    10.1093/hmg/ddw349
  158. Pires-Luís, A.S.; Vieira-Coimbra, M.; João Ferreira, M.; Ramalho-Carvalho, J.; Costa-Pinheiro, P.; Antunes, L.; Dias, P.C.; et al. "Prognostic significance of MST1R dysregulation in renal cell tumors". American Journal of Cancer Research 6 8 (2016): 1799-1811. http://www.scopus.com/inward/record.url?eid=2-s2.0-85000789440&partnerID=MN8TOARS.
  159. Bonilla, C.; Lewis, S.J.; Martin, R.M.; Donovan, J.L.; Hamdy, F.C.; Neal, D.E.; Eeles, R.; et al. "Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort". BMC Medicine 14 1 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-85007425384&partnerID=MN8TOARS.
    10.1186/s12916-016-0602-x
  160. Rodrigues, D.; Jerónimo, C.; Henrique, R.; Belo, L.; De Lourdes Bastos, M.; De Pinho, P.G.; Carvalho, M.. "Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems". International Journal of Cancer 139 2 (2016): 256-268. http://www.scopus.com/inward/record.url?eid=2-s2.0-84959440194&partnerID=MN8TOARS.
    10.1002/ijc.30016
  161. Silva, M.P.; Barros-Silva, J.D.; Vieira, J.; Lisboa, S.; Torres, L.; Correia, C.; Vieira-Coimbra, M.; et al. "NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer". Genes Chromosomes and Cancer 55 4 (2016): 365-374. http://www.scopus.com/inward/record.url?eid=2-s2.0-84958748922&partnerID=MN8TOARS.
    10.1002/gcc.22340
  162. Bartosch, C.; Monteiro-Reis, S.; Vieira, R.; Pereira, A.; Rodrigues, M.; Jerónimo, C.; Lopes, J.M.. "Endometrial endometrioid carcinoma metastases show decreased ER-alpha and PR-A expression compared to matched primary tumors". PLoS ONE 10 8 (2015): http://www.scopus.com/inward/record.url?eid=2-s2.0-84941985240&partnerID=MN8TOARS.
    10.1371/journal.pone.0134969
  163. Martins, A.T.; Carneiro, I.; Monteiro-Reis, S.; Lobo, J.; Luís, A.; Jerónimo, C.; Henrique, R.. "Frozen in translation: Biobanks as a tool for cancer research". Journal of Intellectual Disability - Diagnosis and Treatment 3 2 (2015): 51-62. http://www.scopus.com/inward/record.url?eid=2-s2.0-85038250749&partnerID=MN8TOARS.
    10.6000/2292-2598.2015.03.02.2
  164. Vieira, F.Q.; Costa-Pinheiro, P.; Almeida-Rios, D.; Graça, I.; Monteiro-Reis, S.; Simões-Sousa, S.; Carneiro, I.; et al. "SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3". Oncotarget 6 15 (2015): 13644-13657. http://www.scopus.com/inward/record.url?eid=2-s2.0-84979900432&partnerID=MN8TOARS.
    10.18632/oncotarget.3767
  165. Bartosch, C.; Gomes, B.; Jerónimo, C.; Lopes, J.M.. "Endometrial carcinoma in Portugal: Demographic, diagnostic and treatment changes in the last 5 decades". International Journal of Gynecological Pathology 34 2 (2015): 159-168. http://www.scopus.com/inward/record.url?eid=2-s2.0-84923643298&partnerID=MN8TOARS.
    10.1097/PGP.0000000000000124
  166. Costa-Pinheiro, P.; Ramalho-Carvalho, J.; Vieira, F.Q.; Torres-Ferreira, J.; Oliveira, J.; Gonçalves, C.S.; Costa, B.M.; Henrique, R.; Jerónimo, C.. "MicroRNA-375 plays a dual role in prostate carcinogenesis". Clinical Epigenetics 7 1 (2015): 1-14. http://www.scopus.com/inward/record.url?eid=2-s2.0-84960097977&partnerID=MN8TOARS.
    10.1186/s13148-015-0076-2
  167. Santos, J.; Mesquita, D.; Barros-Silva, J.D.; Jerónimo, C.; Henrique, R.; Morais, A.; Paulo, P.; Teixeira, M.R.. "Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements". Oncoscience 2 5 (2015): 497-507. http://www.scopus.com/inward/record.url?eid=2-s2.0-84958552285&partnerID=MN8TOARS.
    10.18632/oncoscience.142
  168. Maia, S.; Cardoso, M.; Pinto, P.; Pinheiro, M.; Santos, C.; Peixoto, A.; Bento, M.J.; et al. "Identification of two novel HOXB13 germline mutations in Portuguese prostate cancer patients". PLoS ONE 10 7 (2015): http://www.scopus.com/inward/record.url?eid=2-s2.0-84941354860&partnerID=MN8TOARS.
    10.1371/journal.pone.0132728
  169. Costa-Pinheiro, P.; Montezuma, D.; Henrique, R.; Jerónimo, C.. "Diagnostic and prognostic epigenetic biomarkers in cancer". Epigenomics 7 6 (2015): 1003-1015. http://www.scopus.com/inward/record.url?eid=2-s2.0-84947549210&partnerID=MN8TOARS.
    10.2217/epi.15.56
  170. Pires-Luís, A.S.; Vieira-Coimbra, M.; Vieira, F.Q.; Costa-Pinheiro, P.; Silva-Santos, R.; Dias, P.C.; Antunes, L.; et al. "Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication". Epigenetics 10 11 (2015): 1033-1043. http://www.scopus.com/inward/record.url?eid=2-s2.0-84962016106&partnerID=MN8TOARS.
    10.1080/15592294.2015.1103578
  171. Vieira-Coimbra, M.; Henrique, R.; Jerónimo, C.. "New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours". European Journal of Clinical Investigation 45 s1 (2015): 16-24. http://www.scopus.com/inward/record.url?eid=2-s2.0-84919372520&partnerID=MN8TOARS.
    10.1111/eci.12360
  172. Montezuma, D.; Henrique, R.; Jer�nimo, C.. "Altered expression of histone deacetylases in cancer". Critical Reviews in Oncogenesis 20 1-2 (2015): 19-34. http://www.scopus.com/inward/record.url?eid=2-s2.0-84922788875&partnerID=MN8TOARS.
  173. Junqueira-Neto, S.; Vieira, F.Q.; Montezuma, D.; Costa, N.R.; Antunes, L.; Baptista, T.; Oliveira, A.I.; et al. "Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder". Molecular Carcinogenesis 54 7 (2015): 523-531. http://www.scopus.com/inward/record.url?eid=2-s2.0-84930754725&partnerID=MN8TOARS.
    10.1002/mc.22117
  174. Davies, N.M.; Gaunt, T.R.; Lewis, S.J.; Holly, J.; Donovan, J.L.; Hamdy, F.C.; Kemp, J.P.; et al. "The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium". Cancer Causes and Control 26 11 (2015): 1603-1616. http://www.scopus.com/inward/record.url?eid=2-s2.0-84943363498&partnerID=MN8TOARS.
    10.1007/s10552-015-0654-9
  175. Chen, L.-M.; Chang, M.; Dai, Y.; Chai, K.X.; Dyrskjøt, L.; Sanchez-Carbayo, M.; Szarvas, T.; et al. "External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort". Cancer Epidemiology Biomarkers and Prevention 23 9 (2014): 1804-1812. http://www.scopus.com/inward/record.url?eid=2-s2.0-84907164391&partnerID=MN8TOARS.
    10.1158/1055-9965.EPI-14-0029
  176. Rodrigues, Â.; Freitas, R.; Nogueira-Silva, P.; Jerónimo, C.; Henrique, R.. "Biopsy sampling and histopathological markers for diagnosis of prostate cancer". Expert Review of Anticancer Therapy 14 11 (2014): 1323-1336. http://www.scopus.com/inward/record.url?eid=2-s2.0-84910095476&partnerID=MN8TOARS.
    10.1586/14737140.2014.965688
  177. Almeida, M.; Costa, V.L.; Costa, N.R.; Ramalho-Carvalho, J.; Baptista, T.; Ribeiro, F.R.; Paulo, P.; et al. "Epigenetic regulation of EFEMP1 in prostate cancer: Biological relevance and clinical potential". Journal of Cellular and Molecular Medicine 18 11 (2014): 2287-2297. http://www.scopus.com/inward/record.url?eid=2-s2.0-84911154872&partnerID=MN8TOARS.
    10.1111/jcmm.12394
  178. Graça, I.; Sousa, E.J.; Costa-Pinheiro, P.; Vieira, F.Q.; Torres-Ferreira, J.; Martins, M.G.; Henrique, R.; Jerónimo, C.. "Anti-neoplastic properties of hydralazine in prostate cancer". Oncotarget 5 15 (2014): 5950-5964. http://www.scopus.com/inward/record.url?eid=2-s2.0-84906279008&partnerID=MN8TOARS.
    10.18632/oncotarget.1909
  179. Costa-Pinheiro, P.; Patel, H.R.H.; Henrique, R.; Jerónimo, C.. "Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer". Expert Review of Anticancer Therapy 14 11 (2014): 1349-1358. http://www.scopus.com/inward/record.url?eid=2-s2.0-84910100075&partnerID=MN8TOARS.
    10.1586/14737140.2014.952288
  180. Graça, I.; Sousa, E.J.; Baptista, T.; Almeida, M.; Ramalho-Carvalho, J.; Palmeira, C.; Henrique, R.; Jerónimo, C.. "Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells". Current Pharmaceutical Design 20 11 (2014): 1803-1811. http://www.scopus.com/inward/record.url?eid=2-s2.0-84903700216&partnerID=MN8TOARS.
    10.2174/13816128113199990516
  181. Monteiro-Reis, S.; Leça, L.; Almeida, M.; Antunes, L.; Monteiro, P.; Dias, P.C.; Morais, A.; et al. "Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation". European Journal of Cancer 50 1 (2014): 226-233. http://www.scopus.com/inward/record.url?eid=2-s2.0-84891633302&partnerID=MN8TOARS.
    10.1016/j.ejca.2013.08.025
  182. Henrique, R.; Jerónimo, C.. "DNA hypomethylation in plasma as a cancer biomarker: When less is more?". Expert Review of Molecular Diagnostics 14 4 (2014): 419-422. http://www.scopus.com/inward/record.url?eid=2-s2.0-84899016525&partnerID=MN8TOARS.
    10.1586/14737159.2014.905203
  183. Jerónimo, C.; Henrique, R.. "Epigenetic biomarkers in urological tumors: A systematic review". Cancer Letters 342 2 (2014): 264-274. http://www.scopus.com/inward/record.url?eid=2-s2.0-84888198328&partnerID=MN8TOARS.
    10.1016/j.canlet.2011.12.026
  184. Vieira, F.Q.; Costa-Pinheiro, P.; Ramalho-Carvalho, J.; Pereira, A.; Menezes, F.D.; Antunes, L.; Carneiro, I.; et al. "Deregulated expression of selected histone methylases and demethylases in prostate carcinoma". Endocrine-Related Cancer 21 1 (2014): 51-61. http://www.scopus.com/inward/record.url?eid=2-s2.0-84893591021&partnerID=MN8TOARS.
    10.1530/ERC-13-0375
  185. Monteiro, F.L.; Baptista, T.; Amado, F.; Vitorino, R.; Jerónimo, C.; Helguero, L.A.. "Expression and functionality of histone H2A variants in cancer". Oncotarget 5 11 (2014): 3428-3443. http://www.scopus.com/inward/record.url?eid=2-s2.0-84903527222&partnerID=MN8TOARS.
    10.18632/oncotarget.2007
  186. Monteiro, M.; Carvalho, M.; Henrique, R.; Jerónimo, C.; Moreira, N.; De Lourdes Bastos, M.; De Pinho, P.G.. "Analysis of volatile human urinary metabolome by solid-phase microextraction in combination with gas chromatography-mass spectrometry for biomarker discovery: Application in a pilot study to discriminate patients with renal cell carcinoma". European Journal of Cancer 50 11 (2014): 1993-2002. http://www.scopus.com/inward/record.url?eid=2-s2.0-84902252993&partnerID=MN8TOARS.
    10.1016/j.ejca.2014.04.011
  187. Mesquita, B.; Lopes, P.; Rodrigues, A.; Pereira, D.; Afonso, M.; Leal, C.; Henrique, R.; et al. "Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes". Breast Cancer Research and Treatment 138 1 (2013): 37-45. http://www.scopus.com/inward/record.url?eid=2-s2.0-84874660862&partnerID=MN8TOARS.
    10.1007/s10549-013-2408-2
  188. Ramalho-Carvalho, J.; Pires, M.; Lisboa, S.; Graça, I.; Rocha, P.; Barros-Silva, J.D.; Savva-Bordalo, J.; et al. "Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations". PLoS ONE 8 3 (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84874862608&partnerID=MN8TOARS.
    10.1371/journal.pone.0058206
  189. Barros-Silva, J.D.; Paulo, P.; Bakken, A.C.; Cerveira, N.; Løvf, M.; Henrique, R.; Jerónimo, C.; et al. "Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer". Neoplasia (United States) 15 7 (2013): 720-726. http://www.scopus.com/inward/record.url?eid=2-s2.0-84879632065&partnerID=MN8TOARS.
    10.1593/neo.13232
  190. Jin, Y.; Qu, S.; Tesikova, M.; Wang, L.; Kristian, A.; Mælandsmo, G.M.; Kong, H.; et al. "Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer". Proceedings of the National Academy of Sciences of the United States of America 110 28 (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84879893820&partnerID=MN8TOARS.
    10.1073/pnas.1304318110
  191. Sousa, E.J.; Graça, I.; Baptista, T.; Vieira, F.Q.; Palmeira, C.; Henrique, R.; Jerónimo, C.. "Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing". Epigenetics 8 5 (2013): 548-558. http://www.scopus.com/inward/record.url?eid=2-s2.0-84877357686&partnerID=MN8TOARS.
    10.4161/epi.24519
  192. Pértega-Gomes, N.; Vizcaíno, J.R.; Gouveia, C.; Jerõnimo, C.; Henrique, R.M.; Lopes, C.; Baltazar, F.. "Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer". Prostate 73 7 (2013): 763-769. http://www.scopus.com/inward/record.url?eid=2-s2.0-84874219218&partnerID=MN8TOARS.
    10.1002/pros.22620
  193. Silva-Santos, R.M.; Costa-Pinheiro, P.; Luis, A.; Antunes, L.; Lobo, F.; Oliveira, J.; Henrique, R.; Jerónimo, C.. "MicroRNA profile: A promising ancillary tool for accurate renal cell tumour diagnosis". British Journal of Cancer 109 10 (2013): 2646-2653. http://www.scopus.com/inward/record.url?eid=2-s2.0-84887836420&partnerID=MN8TOARS.
    10.1038/bjc.2013.552
  194. Patrício, P.; Ramalho-Carvalho, J.; Costa-Pinheiro, P.; Almeida, M.; Barros-Silva, J.D.; Vieira, J.; Dias, P.C.; et al. "Deregulation of PAX2 expression in renal cell tumours: Mechanisms and potential use in differential diagnosis". Journal of Cellular and Molecular Medicine 17 8 (2013): 1048-1058. http://www.scopus.com/inward/record.url?eid=2-s2.0-84888205093&partnerID=MN8TOARS.
    10.1111/jcmm.12090
  195. Baptista, T.; Graça, I.; Sousa, E.J.; Oliveira, A.I.; Costa, N.R.; Costa-Pinheiro, P.; Amado, F.; Henrique, R.; Jerónimo, C.. "Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer". Oncotarget 4 10 (2013): 1673-1685. http://www.scopus.com/inward/record.url?eid=2-s2.0-84886743585&partnerID=MN8TOARS.
    10.18632/oncotarget.1237
  196. Henrique, R.; Oliveira, A.I.; Costa, V.L.; Baptista, T.; Martins, A.T.; Morais, A.; Oliveira, J.; Jerónimo, C.. "Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer". BMC Genomics 14 1 (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84890290106&partnerID=MN8TOARS.
    10.1186/1471-2164-14-898
  197. Paulo, P.; Ribeiro, F.R.; Santos, J.; Mesquita, D.; Almeida, M.; Barros-Silva, J.D.; Itkonen, H.; et al. "Molecular Subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements". Neoplasia (United States) 14 7 (2012): 600-611. http://www.scopus.com/inward/record.url?eid=2-s2.0-84865619515&partnerID=MN8TOARS.
    10.1593/neo.12600
  198. Oliveira, A.I.; Jerónimo, C.; Henrique, R.. "Moving forward in bladder cancer detection and diagnosis: The role of epigenetic biomarkers". Expert Review of Molecular Diagnostics 12 8 (2012): 871-878. http://www.scopus.com/inward/record.url?eid=2-s2.0-84871301018&partnerID=MN8TOARS.
    10.1586/erm.12.114
  199. Paulo, P.; Barros-Silva, J.D.; Ribeiro, F.R.; Ramalho-Carvalho, J.; Jerónimo, C.; Henrique, R.; Lind, G.E.; et al. "FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer". Genes Chromosomes and Cancer 51 3 (2012): 240-249. http://www.scopus.com/inward/record.url?eid=2-s2.0-84855480278&partnerID=MN8TOARS.
    10.1002/gcc.20948
  200. Camões, M.J.; Paulo, P.; Ribeiro, F.R.; Barros-Silva, J.D.; Almeida, M.; Costa, V.L.; Cerveira, N.; et al. "Potential Downstream Target Genes of Aberrant ETS Transcription Factors Are Differentially Affected in Ewing's Sarcoma and Prostate Carcinoma". PLoS ONE 7 11 (2012): http://www.scopus.com/inward/record.url?eid=2-s2.0-84869748097&partnerID=MN8TOARS.
    10.1371/journal.pone.0049819
  201. Henrique, R.; Luís, A.S.; Jerónimo, C.. "The epigenetics of renal cell tumors: From biology to biomarkers". Frontiers in Genetics 3 MAY (2012): http://www.scopus.com/inward/record.url?eid=2-s2.0-84875085619&partnerID=MN8TOARS.
    10.3389/fgene.2012.00094
  202. Valente, M.J.; Henrique, R.; Vilas-Boas, V.; Silva, R.; Bastos, M.D.L.; Carvalho, F.; Guedes De Pinho, P.; Carvalho, M.. "Cocaine-induced kidney toxicity: An in vitro study using primary cultured human proximal tubular epithelial cells". Archives of Toxicology 86 2 (2012): 249-261. http://www.scopus.com/inward/record.url?eid=2-s2.0-84856951491&partnerID=MN8TOARS.
    10.1007/s00204-011-0749-3
  203. Valente, M.J.; Henrique, R.; Costa, V.L.; Jerónimo, C.; Carvalho, F.; Bastos, M.L.; de Pinho, P.G.; Carvalho, M.. "A rapid and simple procedure for the establishment of human normal and cancer renal primary cell cultures from surgical specimens". PLoS ONE 6 5 (2011): http://www.scopus.com/inward/record.url?eid=2-s2.0-79955761537&partnerID=MN8TOARS.
    10.1371/journal.pone.0019337
  204. Carvalho, A.L.; Henrique, R.; Jeronimo, C.; Nayak, C.S.; Reddy, A.N.; Hoque, M.O.; Chang, S.; et al. "Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance". Clinical Cancer Research 17 14 (2011): 4782-4789. http://www.scopus.com/inward/record.url?eid=2-s2.0-79960435645&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-11-0324
  205. Paiva, F.; Duarte-Pereira, S.; Costa, V.L.; Ramalho-Carvalho, J.; Patrício, P.; Ribeiro, F.R.; Lobo, F.; et al. "Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms". DNA and Cell Biology 30 2 (2011): 85-90. http://www.scopus.com/inward/record.url?eid=2-s2.0-79551639948&partnerID=MN8TOARS.
    10.1089/dna.2010.1108
  206. Duarte-Pereira, S.; Paiva, F.; Costa, V.L.; Ramalho-Carvalho, J.; Savva-Bordalo, J.; Rodrigues, Â.; Ribeiro, F.R.; et al. "Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma". European Journal of Cancer 47 7 (2011): 1106-1114. http://www.scopus.com/inward/record.url?eid=2-s2.0-79953701620&partnerID=MN8TOARS.
    10.1016/j.ejca.2010.12.025
  207. Martins, A.T.; Monteiro, P.; Ramalho-Carvalho, J.; Costa, V.L.; Dinis-Ribeiro, M.; Leal, C.; Henrique, R.; Jerónimo, C.. "High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions". Breast Cancer Research and Treatment 129 1 (2011): 1-9. http://www.scopus.com/inward/record.url?eid=2-s2.0-79960847694&partnerID=MN8TOARS.
    10.1007/s10549-010-1160-0
  208. Costa, V.L.; Henrique, R.; Danielsen, S.A.; Eknaes, M.; Patrício, P.; Morais, A.; Oliveira, J.; et al. "TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers". Epigenetics 6 9 (2011): 1120-1130. http://www.scopus.com/inward/record.url?eid=2-s2.0-80052585520&partnerID=MN8TOARS.
    10.4161/epi.6.9.16376
  209. Ribeiro, F.R.; Paulo, P.; Costa, V.L.; Barros-Silva, J.D.; Ramalho-Carvalho, J.; Jerónimo, C.; Henrique, R.; et al. "Cysteine-Rich secretory protein-3 (CRISP3) is strongly Up-Regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene". PLoS ONE 6 7 (2011): http://www.scopus.com/inward/record.url?eid=2-s2.0-79960632568&partnerID=MN8TOARS.
    10.1371/journal.pone.0022317
  210. Barros-Silva, J.D.; Ribeiro, F.R.; Rodrigues, Â.; Cruz, R.; Martins, A.T.; Jerónimo, C.; Henrique, R.; Teixeira, M.R.. "Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer". Genes Chromosomes and Cancer 50 8 (2011): 662-671. http://www.scopus.com/inward/record.url?eid=2-s2.0-79958025241&partnerID=MN8TOARS.
    10.1002/gcc.20888
  211. Jerónimo, C.; Bastian, P.J.; Bjartell, A.; Carbone, G.M.; Catto, J.W.F.; Clark, S.J.; Henrique, R.; Nelson, W.G.; Shariat, S.F.. "Epigenetics in prostate cancer: Biologic and clinical relevance". European Urology 60 4 (2011): 753-766. http://www.scopus.com/inward/record.url?eid=2-s2.0-80052260149&partnerID=MN8TOARS.
    10.1016/j.eururo.2011.06.035
  212. Pértega-Gomes, N.; Vizcaíno, J.R.; Miranda-Gonçalves, V.; Pinheiro, C.; Silva, J.; Pereira, H.; Monteiro, P.; et al. "Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer.". BMC cancer 11 (2011): http://www.scopus.com/inward/record.url?eid=2-s2.0-84856609812&partnerID=MN8TOARS.
  213. Valente, M.J.; Baltazar, A.F.; Henrique, R.; Estevinho, L.; Carvalho, M.. "Biological activities of Portuguese propolis: Protection against free radical-induced erythrocyte damage and inhibition of human renal cancer cell growth in vitro". Food and Chemical Toxicology 49 1 (2011): 86-92. http://www.scopus.com/inward/record.url?eid=2-s2.0-78650285093&partnerID=MN8TOARS.
    10.1016/j.fct.2010.10.001
  214. Carvalho, J.R.; Filipe, L.; Costa, V.L.; Ribeiro, F.R.; Martins, A.T.; Teixeira, M.R.; Jerónimo, C.; Henrique, R.. "Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer". Apoptosis 15 8 (2010): 956-965. http://www.scopus.com/inward/record.url?eid=2-s2.0-77956905086&partnerID=MN8TOARS.
    10.1007/s10495-010-0508-6
  215. Savva-Bordalo, J.; Ramalho-Carvalho, J.; Pinheiro, M.; Costa, V.L.; Rodrigues, T.; Dias, P.C.; Veiga, I.; et al. "Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients". BMC Cancer 10 (2010): http://www.scopus.com/inward/record.url?eid=2-s2.0-77956472030&partnerID=MN8TOARS.
    10.1186/1471-2407-10-470
  216. Carvalho, M.; Ferreira, P.J.; Mendes, V.S.; Silva, R.; Pereira, J.A.; Jerónimo, C.; Silva, B.M.. "Human cancer cell antiproliferative and antioxidant activities of Juglans regia L.". Food and Chemical Toxicology 48 1 (2010): 441-447. http://www.scopus.com/inward/record.url?eid=2-s2.0-72149130530&partnerID=MN8TOARS.
    10.1016/j.fct.2009.10.043
  217. Costa, V.L.; Henrique, R.; Ribeiro, F.R.; Carvalho, J.R.; Oliveira, J.; Lobo, F.; Teixeira, M.R.; Jerónimo, C.. "Epigenetic regulation of Wnt signaling pathway in urological cancer". Epigenetics 5 4 (2010): 343-351. http://www.scopus.com/inward/record.url?eid=2-s2.0-77954662435&partnerID=MN8TOARS.
    10.4161/epi.5.4.11749
  218. Vieira, J.; Henrique, R.; Ribeiro, F.R.; Barros-Silva, J.D.; Peixoto, A.; Santos, C.; Pinheiro, M.; et al. "Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies". Genes Chromosomes and Cancer 49 10 (2010): 935-947. http://www.scopus.com/inward/record.url?eid=2-s2.0-77957877009&partnerID=MN8TOARS.
    10.1002/gcc.20805
  219. Costa, V.L.; Henrique, R.; Danielsen, S.A.; Duarte-Pereira, S.; Eknaes, M.; Skotheim, R.I.; Rodrigues, Â.; et al. "Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples". Clinical Cancer Research 16 23 (2010): 5842-5851. http://www.scopus.com/inward/record.url?eid=2-s2.0-78650354147&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-10-1312
  220. Jerónimo, C.; Esteller, M.. "DNA methylation markers for prostate cancer with a stem cell twist". Cancer Prevention Research 3 9 (2010): 1053-1055. http://www.scopus.com/inward/record.url?eid=2-s2.0-77956398136&partnerID=MN8TOARS.
    10.1158/1940-6207.CAPR-10-0131
  221. Carvalho, M.; Jerónimo, C.; Valentão, P.; Andrade, P.B.; Silva, B.M.. "Green tea: A promising anticancer agent for renal cell carcinoma". Food Chemistry 122 1 (2010): 49-54. http://www.scopus.com/inward/record.url?eid=2-s2.0-77950593368&partnerID=MN8TOARS.
    10.1016/j.foodchem.2010.02.014
  222. Soares, M.J.; Pinto, M.; Henrique, R.; Vieira, J.; Cerveira, N.; Peixoto, A.; Martins, A.T.; et al. "CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas". Modern Pathology 22 6 (2009): 744-752. http://www.scopus.com/inward/record.url?eid=2-s2.0-67349179639&partnerID=MN8TOARS.
    10.1038/modpathol.2009.43
  223. Liu, J.-W.; Nagpal, J.K.; Jeronimo, C.; Ji, E.L.; Henrique, R.; Myoung, S.K.; Ostrow, K.L.; et al. "Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer". Prostate 68 4 (2008): 418-426. http://www.scopus.com/inward/record.url?eid=2-s2.0-40349103522&partnerID=MN8TOARS.
    10.1002/pros.20709
  224. Hoque, M.O.; Kim, M.S.; Ostrow, K.L.; Liu, J.; Wisman, G.B.A.; Park, H.L.; Poeta, M.L.; et al. "Genome-wide promoter analysis uncovers portions of the cancer methylome". Cancer Research 68 8 (2008): 2661-2670. http://www.scopus.com/inward/record.url?eid=2-s2.0-42349107016&partnerID=MN8TOARS.
    10.1158/0008-5472.CAN-07-5913
  225. Carvalho, A.L.; Jeronimo, C.; Kim, M.M.; Henrique, R.; Zhang, Z.; Hoque, M.O.; Chang, S.; et al. "Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma". Clinical Cancer Research 14 1 (2008): 97-107. http://www.scopus.com/inward/record.url?eid=2-s2.0-40749100687&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-07-0722
  226. Hoque, M.O.; Begum, S.; Brait, M.; Jeronimo, C.; Zahurak, M.; Ostrow, K.L.; Rosenbaum, E.; et al. "Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer". Journal of Urology 179 2 (2008): 743-747. http://www.scopus.com/inward/record.url?eid=2-s2.0-38849165454&partnerID=MN8TOARS.
    10.1016/j.juro.2007.09.019
  227. Pinto, M.; Vieira, J.; Ribeiro, F.R.; Soares, M.J.; Henrique, R.; Oliveira, J.; Jerónimo, C.; Teixeira, M.R.. "Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas". Cellular Oncology 30 5 (2008): 389-395. http://www.scopus.com/inward/record.url?eid=2-s2.0-52449130697&partnerID=MN8TOARS.
    10.3233/CLO-2008-0439
  228. Jeronimo, C.; Monteiro, P.; Henrique, R.; Dinis-Ribeiro, M.; Costa, I.; Costa, V.L.; Filipe, L.; et al. "Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions". Breast Cancer Research and Treatment 109 1 (2008): 27-34. http://www.scopus.com/inward/record.url?eid=2-s2.0-42149087728&partnerID=MN8TOARS.
    10.1007/s10549-007-9620-x
  229. Liu, J.-W.; Nagpal, J.K.; Sun, W.; Lee, J.; Kim, M.S.; Ostrow, K.L.; Zhou, S.; et al. "SsDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer". Clinical Cancer Research 14 12 (2008): 3754-3760. http://www.scopus.com/inward/record.url?eid=2-s2.0-52449108458&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-07-4763
  230. Liu, J.-W.; Myoung, S.K.; Nagpal, J.; Yamashita, K.; Poeta, L.; Chang, X.; Lee, J.; et al. "Quantitative hypermethylation of NMDAR2B in human gastric cancer". International Journal of Cancer 121 9 (2007): 1994-2000. http://www.scopus.com/inward/record.url?eid=2-s2.0-34648833479&partnerID=MN8TOARS.
    10.1002/ijc.22934
  231. Ribeiro, F.R.; Henrique, R.; Martins, A.T.; Jerónimo, C.; Teixeira, M.R.. "Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients". European Urology 52 1 (2007): 116-125. http://www.scopus.com/inward/record.url?eid=2-s2.0-34249039594&partnerID=MN8TOARS.
    10.1016/j.eururo.2006.09.018
  232. Costa, V.L.; Henrique, R.; Ribeiro, F.R.; Pinto, M.; Oliveira, J.; Lobo, F.; Teixeira, M.R.; Jerónimo, C.. "Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors". BMC Cancer 7 (2007): http://www.scopus.com/inward/record.url?eid=2-s2.0-34547779010&partnerID=MN8TOARS.
    10.1186/1471-2407-7-133
  233. Costa, V.L.; Henrique, R.; Jerónimo, C.. "Epigenetic markers for molecular detection of prostate cancer". Disease Markers 23 1-2 (2007): 31-41. http://www.scopus.com/inward/record.url?eid=2-s2.0-33847344764&partnerID=MN8TOARS.
  234. Pinto, M.; Soares, M.J.; Cerveira, N.; Henrique, R.; Ribeiro, F.R.; Oliveira, J.; Jerónimo, C.; Teixeira, M.R.. "Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes". Virchows Archiv 450 4 (2007): 379-385. http://www.scopus.com/inward/record.url?eid=2-s2.0-33947523032&partnerID=MN8TOARS.
    10.1007/s00428-007-0386-7
  235. Henrique, R.M.F.; Costa, V.L.; Jerónimo, C.. "Methylation-based biomarkers for early detection of urological cancer". Critical Reviews in Oncogenesis 13 4 (2007): 265-282. http://www.scopus.com/inward/record.url?eid=2-s2.0-43249124527&partnerID=MN8TOARS.
    10.1615/CritRevOncog.v13.i4.10
  236. Nayak, C.S.; Carvalho, A.L.; Jeronimo, C.; Henrique, R.; Kim, M.M.; Hoque, M.O.; Chang, S.; et al. "Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma". Laryngoscope 117 8 (2007): 1376-1380. http://www.scopus.com/inward/record.url?eid=2-s2.0-34548449339&partnerID=MN8TOARS.
    10.1097/MLG.0b013e31806865a8
  237. Henrique, R.; Ribeiro, F.R.; Fonseca, D.; Hoque, M.O.; Carvalho, A.L.; Costa, V.L.; Pinto, M.; et al. "High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients". Clinical Cancer Research 13 20 (2007): 6122-6129. http://www.scopus.com/inward/record.url?eid=2-s2.0-35948929442&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-07-1042
  238. Henrique, R.M.F.. "New doctorial cancer research: Epigenetic heterogeneity in prostate cancer: Impact of genetic and epigenetic alterations on diagnosis and prognosis". Critical Reviews in Oncogenesis 13 2 (2007): 181-182. http://www.scopus.com/inward/record.url?eid=2-s2.0-37249014413&partnerID=MN8TOARS.
  239. Ribeiro, F.R.; Henrique, R.; Hektoen, M.; Berg, M.; Jerónimo, C.; Teixeira, M.R.; Lothe, R.A.. "Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas". Molecular Cancer 5 (2006): http://www.scopus.com/inward/record.url?eid=2-s2.0-33748968523&partnerID=MN8TOARS.
    10.1186/1476-4598-5-33
  240. Hoque, M.O.; Feng, Q.; Toure, P.; Dem, A.; Critchlow, C.W.; Hawes, S.E.; Wood, T.; et al. "Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer". Journal of Clinical Oncology 24 26 (2006): 4262-4269. http://www.scopus.com/inward/record.url?eid=2-s2.0-33749024160&partnerID=MN8TOARS.
    10.1200/JCO.2005.01.3516
  241. Ribeiro, F.R.; Diep, C.B.; Jerónimo, C.; Henrique, R.; Lopes, C.; Eknæs, M.; Lingjærde, O.C.; Lothe, R.A.; Teixeira, M.R.. "Statistical dissection of genetic pathways involved in prostate carcinogenesis". Genes Chromosomes and Cancer 45 2 (2006): 154-163. http://www.scopus.com/inward/record.url?eid=2-s2.0-31944449020&partnerID=MN8TOARS.
    10.1002/gcc.20279
  242. Ribeiro, F.R.; Jerónimo, C.; Henrique, R.; Fonseca, D.; Oliveira, J.; Lothe, R.A.; Teixeira, M.R.. "8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects". Clinical Cancer Research 12 13 (2006): 3961-3970. http://www.scopus.com/inward/record.url?eid=2-s2.0-33746055324&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-05-1977
  243. Cerveira, N.; Ribeiro, F.R.; Peixoto, A.; Costa, V.; Henrique, R.; Jerónimo, C.; Teixeira, M.R.. "TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions". Neoplasia 8 10 (2006): 826-832. http://www.scopus.com/inward/record.url?eid=2-s2.0-33749870551&partnerID=MN8TOARS.
    10.1593/neo.06427
  244. Henrique, R.; Costa, V.L.; Cerveira, N.; Carvalho, A.L.; Hoque, M.O.; Ribeiro, F.R.; Oliveira, J.; et al. "Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer". Journal of Molecular Medicine 84 11 (2006): 911-918. http://www.scopus.com/inward/record.url?eid=2-s2.0-33750435596&partnerID=MN8TOARS.
    10.1007/s00109-006-0099-4
  245. Pinto, C.; Veiga, I.; Pinheiro, M.; Mesquita, B.; Jerónimo, C.; Sousa, O.; Fragoso, M.; et al. "MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease". British Journal of Cancer 95 6 (2006): 752-756. http://www.scopus.com/inward/record.url?eid=2-s2.0-33748565629&partnerID=MN8TOARS.
    10.1038/sj.bjc.6603318
  246. Carvalho, A.L.; Chuang, A.; Jiang, W.-W.; Lee, J.; Begum, S.; Poeta, L.; Zhao, M.; et al. "Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma". Cancer Research 66 19 (2006): 9401-9407. http://www.scopus.com/inward/record.url?eid=2-s2.0-33750363705&partnerID=MN8TOARS.
    10.1158/0008-5472.CAN-06-1073
  247. Henrique, R.; Jerónimo, C.; Teixeira, M.R.; Hoque, M.O.; Carvalho, A.L.; Pais, I.; Ribeiro, F.R.; et al. "Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: Clues for clonal progression in prostate carcinogenesis". Molecular Cancer Research 4 1 (2006): 1-8. http://www.scopus.com/inward/record.url?eid=2-s2.0-32944480348&partnerID=MN8TOARS.
    10.1158/1541-7786.MCR-05-0113
  248. Henrique, R.; Jerónimo, C.; Hoque, M.O.; Carvalho, A.L.; Oliveira, J.; Teixeira, M.R.; Lopes, C.; Sidransky, D.. "Frequent 14-3-3s promoter methylation in benign and malignant prostate lesions". DNA and Cell Biology 24 4 (2005): 264-269. http://www.scopus.com/inward/record.url?eid=2-s2.0-16844374138&partnerID=MN8TOARS.
    10.1089/dna.2005.24.264
  249. Jerónimo, C.. "Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers". Future Oncology 1 2 (2005): 197-200. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646439763&partnerID=MN8TOARS.
    10.1517/14796694.1.2.197
  250. Paredes, J.; Albergaria, A.; Oliveira, J.T.; Jeronimo, C.; Milanezi, F.; Schmitt, F.C.. "P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation". Clinical Cancer Research 11 16 (2005): 5869-5877. http://www.scopus.com/inward/record.url?eid=2-s2.0-23844489449&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-05-0059
  251. Henrique, R.; Jerónimo, C.; Hoque, M.O.; Nomoto, S.; Carvalho, A.L.; Costa, V.L.; Oliveira, J.; et al. "MT1G hypermethylation is associated with higher tumor stage in prostate cancer". Cancer Epidemiology Biomarkers and Prevention 14 5 (2005): 1274-1278. http://www.scopus.com/inward/record.url?eid=2-s2.0-20844459807&partnerID=MN8TOARS.
    10.1158/1055-9965.EPI-04-0659
  252. Hoque, M.O.; Topaloglu, O.; Begum, S.; Henrique, R.; Rosenbaum, E.; Van Criekinge, W.; Westra, W.H.; Sidransky, D.. "Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects". Journal of Clinical Oncology 23 27 (2005): 6569-6575. http://www.scopus.com/inward/record.url?eid=2-s2.0-27244450828&partnerID=MN8TOARS.
    10.1200/JCO.2005.07.009
  253. Jerónimo, C.; Henrique, R.; Hoque, M.O.; Ribeiro, F.R.; Oliveira, J.; Fonseca, D.; Teixeira, M.R.; Lopes, C.; Sidransky, D.. "Quantitative RARß2 hypermethylation: A promising prostate cancer marker". Clinical Cancer Research 10 12 I (2004): 4010-4014. http://www.scopus.com/inward/record.url?eid=2-s2.0-3042619078&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-03-0643
  254. Reesink-Peters, N.; Wisman, G.B.A.; Jéronimo, C.; Tokumaru, C.Y.; Cohen, Y.; Dong, S.M.; Klip, H.G.; et al. "Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: A feasibility study". Molecular Cancer Research 2 5 (2004): 289-295. http://www.scopus.com/inward/record.url?eid=2-s2.0-3543067045&partnerID=MN8TOARS.
  255. Hoque, M.O.; Begum, S.; Topaloglu, O.; Jeronimo, C.; Mambo, E.; Westra, W.H.; Califano, J.A.; Sidransky, D.. "Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer". Cancer Research 64 15 (2004): 5511-5517. http://www.scopus.com/inward/record.url?eid=2-s2.0-3442894720&partnerID=MN8TOARS.
    10.1158/0008-5472.CAN-04-0799
  256. Jerónimo, C.; Henrique, R.; Oliveira, J.; Lobo, F.; Pais, I.; Teixeira, M.R.; Lopes, C.. "Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer". Journal of Clinical Pathology 57 8 (2004): 872-876. http://www.scopus.com/inward/record.url?eid=2-s2.0-4043078431&partnerID=MN8TOARS.
    10.1136/jcp.2003.014555
  257. Henrique, R.; Jerónimo, C.. "Molecular detection of prostate cancer: A role for GSTP1 hypermethylation". European Urology 46 5 (2004): 660-669. http://www.scopus.com/inward/record.url?eid=2-s2.0-5144220196&partnerID=MN8TOARS.
    10.1016/j.eururo.2004.06.014
  258. Jerónimo, C.; Henrique, R.; Hoque, M.O.; Mambo, E.; Ribeiro, F.R.; Varzim, G.; Oliveira, J.; et al. "A quantitative promoter methylation profile of prostate cancer". Clinical Cancer Research 10 24 (2004): 8472-8478. http://www.scopus.com/inward/record.url?eid=2-s2.0-19944429845&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-04-0894
  259. Begum, S.; Rosenbaum, E.; Henrique, R.; Cohen, Y.; Sidransky, D.; Westra, W.H.. "BRAF mutations in anaplastic thyroid carcinoma: Implications for tumor origin, diagnosis and treatment". Modern Pathology 17 11 (2004): 1359-1363. http://www.scopus.com/inward/record.url?eid=2-s2.0-8144230516&partnerID=MN8TOARS.
    10.1038/modpathol.3800198
  260. Cerveira, N.; Torres, L.; Rocha, P.; Bizarro, S.; Pereira, D.; Abreu, J.; Henrique, R.; Teixeira, M.R.; Castedo, S.. "Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients". International Journal of Cancer 108 4 (2004): 592-595. http://www.scopus.com/inward/record.url?eid=2-s2.0-0348048477&partnerID=MN8TOARS.
    10.1002/ijc.11609
  261. Cherdwongchareonsuk, D.; Águas, A.P.; Henrique, R.; Upatham, S.; Pereira, A.S.. "Toxic effects of selenium inhalation: Acute damage of the respiratory system of mice". Human and Experimental Toxicology 22 10 (2003): 551-557. http://www.scopus.com/inward/record.url?eid=2-s2.0-0344466401&partnerID=MN8TOARS.
    10.1191/0960327103ht396oa
  262. Marcos, R.; Rocha, E.; Henrique, R.M.F.; Monteiro, R.A.F.. "A new approach to an unbiased estimate of the hepatic stellate cell index in the rat liver: An example in healthy conditions". Journal of Histochemistry and Cytochemistry 51 8 (2003): 1101-1104. http://www.scopus.com/inward/record.url?eid=2-s2.0-0042745504&partnerID=MN8TOARS.
  263. Tokumaru, Y.; Nomoto, S.; Jerónimo, C.; Henrique, R.; Harden, S.; Trink, B.; Sidransky, D.. "Biallelic inactivation of the RIZ1 gene in human gastric cancer". Oncogene 22 44 (2003): 6954-6958. http://www.scopus.com/inward/record.url?eid=2-s2.0-0242406711&partnerID=MN8TOARS.
    10.1038/sj.onc.1206403
  264. Jerónimo, C.; Henrique, R.; Campos, P.F.; Oliveira, J.; Caballero, O.L.; Lopes, C.; Sidransky, D.. "Endothelin B receptor gene hypermethylation in prostate adenocarcinoma". Journal of Clinical Pathology 56 1 (2003): 52-55. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037245645&partnerID=MN8TOARS.
    10.1136/jcp.56.1.52
  265. Jerónimo, C.; Costa, I.; Conceição Martins, M.; Monteiro, P.; Lisboa, S.; Palmeira, C.; Henrique, R.; Teixeira, M.R.; Lopes, C.. "Detection of gene promoter hypermethylation in fine needle washings from breast lesions". Clinical Cancer Research 9 9 (2003): 3413-3417. http://www.scopus.com/inward/record.url?eid=2-s2.0-0042334827&partnerID=MN8TOARS.
  266. Jerónimo, C.; Varzim, G.; Henrique, R.; Oliveira, J.; Bento, M.J.; Silva, C.; Lopes, C.; Sidransky, D.. "I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma". Cancer Epidemiology Biomarkers and Prevention 11 5 (2002): 445-450. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036095150&partnerID=MN8TOARS.
  267. Jerónimo, C.; Usadel, H.; Henrique, R.; Silva, C.; Oliveira, J.; Lopes, C.; Sidransky, D.. "Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer". Urology 60 6 (2002): 1131-1135. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036899057&partnerID=MN8TOARS.
    10.1016/S0090-4295(02)01949-0
  268. Usadel, H.; Jerónimo, C.; Harden, S.; Engles, J.; Sidransky, D.; Yang, S.; Brabender, J.; Danenberg, K.D.; Danenberg, P.V.. "Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer". Cancer Research 62 2 (2002): 371-375. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037081085&partnerID=MN8TOARS.
  269. Sanchez-Cespedes, M.; Parrella, P.; Nomoto, S.; Cohen, D.; Xiao, Y.; Jeronimo, C.; Koch, W.M.; et al. "Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors". Cancer Research 61 19 (2001): 7015-7019. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035476227&partnerID=MN8TOARS.
  270. Cairns, P.; Esteller, M.; Herman, J.G.; Sidransky, D.; Schoenberg, M.; Jeronimo, C.; Sanchez-Cespedes, M.; et al. "Molecular detection of prostate cancer in urine by GSTP1 hypermethylation". Clinical Cancer Research 7 9 (2001): 2727-2730. http://www.scopus.com/inward/record.url?eid=2-s2.0-0034808413&partnerID=MN8TOARS.
  271. Spafford, M.F.; Koch, W.M.; Reed, A.L.; Califano, J.A.; Xu, L.H.; Eisenberger, C.F.; Yip, L.; et al. "Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis". Clinical Cancer Research 7 3 (2001): 607-612. http://www.scopus.com/inward/record.url?eid=2-s2.0-0034907334&partnerID=MN8TOARS.
  272. Jerónimo, C.; Nomoto, S.; Caballero, O.L.; Usadel, H.; Henrique, R.; Varzim, G.; Oliveira, J.; et al. "Mitochondrial mutations in early stage prostate cancer and bodily fluids". Oncogene 20 37 (2001): 5195-5198. http://www.scopus.com/inward/record.url?eid=2-s2.0-17944367327&partnerID=MN8TOARS.
    10.1038/sj.onc.1204646
  273. Jerónimo, C.; Usadel, H.; Henrique, R.; Oliveira, J.; Lopes, C.; Nelson, W.G.; Sidransky, D.. "Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma". Journal of the National Cancer Institute 93 22 (2001): 1747-1752. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035930097&partnerID=MN8TOARS.
    10.1093/jnci/93.22.1747
  274. Henrique, R.; Azevedo, R.; Bento, M.J.; Domingues, J.C.; Silva, C.; Jerónimo, C.. "Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma". Journal of the American Academy of Dermatology 43 6 (2000): 991-1000. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033664108&partnerID=MN8TOARS.
  275. Leong, P.M.; Lisa Kauffman, C.; Margaret Moresi, J.; Wu, L.; Jeronimo, C.; Sidransky, D.M.; Miller, S.J.. "Basal cell carcinoma-like epidermal changes overlying dermatofibromas often reveal loss of heterozygosity in the PTCH gene [2]". Journal of Investigative Dermatology 113 2 (1999): 279-281. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033513393&partnerID=MN8TOARS.
    10.1046/j.1523-1747.1999.00688.x
  276. Henrique, R.M.F.; Sousa, M.E.; Godinho, M.I.; Costa, I.; Barbosa, I.L.; Lopes, C.A.S.. "Immunophenotyping by flow cytometry of fine needle aspirates in the diagnosis of lymphoproliferative disorders: A retrospective study". Journal of Clinical Laboratory Analysis 13 5 (1999): 224-228. http://www.scopus.com/inward/record.url?eid=2-s2.0-0032880195&partnerID=MN8TOARS.
    10.1002/(SICI)1098-2825(1999)13:5<224::AID-JCLA6>3.0.CO;2-5
Capítulo de livro
  1. Sarmento Ribeiro, Ana Bela; Botelho, Maria Filomena; Gonçalves, Ana Cristina; Melo, Joana Barbosa; Laranjo, Mafalda; Alves, Raquel; Jorge, Joana; et al. "Aging-related neoplasia". In Aging, 547-575. Elsevier, 2023.
    10.1016/b978-0-12-823761-8.00026-4
  2. Matos, Bárbara; Howl, John; Jerónimo, Carmen; Fardilha, Margarida. "Exploring glycolytic adaptations in cancer cells". In Glycolysis: Tissue-specific Metabolic regulation in physio-pathological conditions. Elsevier, 2023.
    No prelo
  3. João Lobo; Carmen Jerónimo; Rui Henrique. "Targeting chromatin remodelers in urological tumors". 2020.
    10.1016/B978-0-12-816422-8.00008-8
  4. Ramalho-Carvalho, J; Henrique, R; Jerónimo, C. "Methylation-Specific PCR". In Methods in Molecular Biology, editado por Jorg Tost, 1868-1868. Alemanha: Springer Berlin Heidelberg, 2018.
    10.1007/978-3-540-47648-1_3686
  5. Vieira, Filipa Quintela; Almeida-Rios, Diogo; Graça, Inês; Henrique, Rui; Jerónimo, Carmen. "Histone Posttranslational Modifications and Chromatin Remodelers in Prostate Cancer". In Epigenetic Biomarkers and Diagnostics, editado por Garcia Gímenez, JL, 447-465. Elsevier, 2016.
    Publicado • 10.1016/b978-0-12-801899-6.00022-x
  6. Henrique, Rui; Jerónimo, Carmen. "GSTP1 Hypermethylation for Prostate Cancer Detection". In Prostate Cancer Screening, 279-288. Humana Press, 2009.
    10.1007/978-1-60327-281-0_19
  7. Jerónimo, C.; Henrique, R.; Sidransky, D.. "Uses of DNA methylation in cancer diagnosis and risk assessment". editado por Esteller, M., 11-26. 2004.
Livro
  1. Jerónimo, Carmen. Histone Modifications in Therapy (Translational epigenetics). Reino Unido: Academic Press 2020. 2020.
    Publicado • Editor
Poster em conferência
  1. Macedo-Silva, Catarina; Angela Albuquerque-Castro; Lencart, Joana; Carneiro, Isa; Nuno Tiago Tavares; Barros-Silva, Daniela; João Lobo; et al. "Epigenetic reprogramming as Hallmark of prostate cancer radiobiology". Trabalho apresentado em Young Researchers Day IPO Porto, 2023.
  2. Macedo-Silva, Catarina; Vera Miranda-Gonçalves; Nuno Tiago Tavares; Barros-Silva, Daniela; Angela Albuquerque-Castro; Lencart, Joana; Carneiro, Isa; et al. "Epigenetic modulation of p53 by GSK-J4 attenuates prostate cancer radioresistance". Trabalho apresentado em ImmunoRad, 2023.
  3. Matos, Bárbara; Monteiro, Maria V.; Bernardino, Raquel L.; Alves, Marco G.; Oliveira, Pedro F.; Gaspar, Vitor; Mano, Joao F.; et al. "Modulação de complexos da proteína fosfatase 1 usando péptidos para tratamento do cancro da próstata". Trabalho apresentado em 5º ENJIO - 5º Encontro nacional de jovens investigadores em oncologia, 2023.
  4. Matos, Bárbara; Monteiro, Maria V.; Bernardino, Raquel L.; Alves, Marco; Oliveira, Pedro; Gaspar, Vitor; Mano, Joao F.; et al. "CAVPENET-induced modulation of PP1 activity suppresses the growth of 2D and 3D prostate cancer cultures by inducing metabolic reprogramming". Trabalho apresentado em Signal regulation by protein phosphatases: Mechanisms and pathways, 2023.
  5. Estêvão, Diogo; da Cruz-Ribeiro, Miguel; Macedo-Silva, Catarina; Jerónimo, Carmen; Olga Sousa; De Wever, Olivier; Maria José Oliveira; Cruz, Tânia. Autor correspondente: da Cruz-Ribeiro, Miguel. "Dissecting the Radiotherapy-mediated changes in Rectal Cancer Immune Profile". Trabalho apresentado em XLVIII SPI Annual Meeting, 2023.
  6. Lima, Ana Rita; Carvalho-Maia, Carina; Jerónimo, Carmen; Henrique, Rui; Aveiro, Susana S.; Melo, Tânia; Domingues, Maria Rosário; et al. "Metabolomics and lipidomics approaches reveal new dysregulations associated with prostate cancer". Trabalho apresentado em 3rd EpiLipidNET General Action Meeting, 2022.

Propriedade Intelectual

Patente
  1. Jerónimo, Carmen. 2012. "Methods and biomarkers for detection of bladder cancer". Noruega.
    Pendente
Pedido provisório de patente
  1. 2024. "Prostate cancer recurrence risk calculator".
    Protegido

Outros

Outra produção
  1. A DNA Methylation-based Test for Esophageal Cancer Detection. Biomarker Research. 2020. Sofia Salta; Catarina Macedo-Silva; Vera Miranda-Gonçalves; Nair Lopes; Davide Gigliano; Rita Guimarães; Mónica Farinha; et al. https://doi.org/10.21203/rs.3.rs-44848/v3.
    10.21203/rs.3.rs-44848/v3
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2023/06 PANDORA - A Pan-European Educational Platform, June 15, 2023; Session Liquid Biopsies: searching for cancer biomarkers; Title: Liquid biopsies: Shifting the cancer screening paradigm (Virtual). PANDORA - A Pan-European Educational Platform
PANDORA - cancer academy-COST INNOVATORS GRANT (Torino, Itália)
2023/05 Clinical Epigenetics International Conference (CLEPIC), Szczecin, Poland, May 24-26, 2023; Session- Epigenetic Biomarkers; Title: Simultaneous early detection of the four major cancers by DNA methylation testing in blood-based liquid biopsies using droplet digital PCR. Clinical Epigenetics International Conference
International Society for Molecular and Clinical Epigenetics (Szczecin, Polónia)
2023/03 EAU23, Milan, Italy, March 10-13, 2023; Session- Liquid biomarkers; Title: State-of-the-art lecture: Novel biomarkers for diagnosis of prostate cancer. European Association of Urology Meeting 2023
European Association of Urology (Milan, Itália)
2022/07 EAU22, Amsterdam, The Netherlands, July 1-4, 2022; Session- Liquid biomarkers in 2022 and beyond: Ready for primetime?; Title: Liquid and tumour biomarkers in prostate cancer. European Association of Urology Meeting 2022
European Association of Urology (Amsterdam, Países Baixos)
2022/07 EAU22, Amsterdam, The Netherlands, July 1-4, 2022; Session- Biomarkers in uro-oncology: From bench to bedside; Title: Non-coding RNAs in liquid biopsy as biomarkers in urological malignancies European Association of Urology Meeting 2022
European Association of Urology (Amsterdam, Países Baixos)
2022/06/09 Clinical Epigenetics International Conference (CLEPIC), Szczecin, Poland, June 8-10, 2022; Session- Cancer Epigenetics; Title: Uncovering the role of the epigenetically-regulated miR-30a/c-5p in renal cancer: from biology to the biomarker potential. Clinical Epigenetics International Conference (CLEPIC)
International Society for Molecular and Clinical Epigenetics (iSMOCLEP). (Szczecin, Polónia)
2022/05/10 Epi-Besançon 2022- Canceropole Grand-Ouest, Besançon, France, May 10-11,2022; Title: Non-coding RNAs in liquid biopsy as urological cancer biomarkers. Epi-Besançon 2022- Canceropole Grand-Ouest, May 10-11,2022
Canceropole Grand-Ouest (Besançon, França)
2021/10/14 II ASPIC-ASEICA International Meeting on Current Trends in Precision Medicine in Cancer, 14-15 October, (Virtual), 2021 Title: DNA promoter methylation of homologous recombination genes: a predictive biomarker for the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. II ASPIC-ASEICA International Meeting – Current Trends in Precision Medicine in Cancer
Associação Portuguesa de Investigação em Cancro (Porto, Portugal)
2019/10/08 Epitranscriptomics in urological tumors, TransPot (Translational Research Network for Prostate Cancer) Training Course, IPO Porto, Porto, Portugal TransPot (Translational Research Network for Prostate Cancer) Training Course
TransPot (Translational Research Network for Prostate Cancer) Training Couse (Porto, Portugal)
2018/06 First Nordic conference on personalized medicine, Nyborg, Denmark, May 30th - June 1st, 2018; Title: Diagnostic and prognostic epigenetic biomarkers in cancer. First Nordic Conference on Personalized Medicine
Danish Society of Clinical Pharmacology (Nyborg, Dinamarca)
2018/03 EAU18, Copenhagen, Denmark, March 18-22, 2018; Title: Signalling pathways implicated in therapy: Resistance in urothelium cancer. EAU18
European Association of Urology (Copenhaga, Dinamarca)
2017/10 The International Bladder Cancer Network 15th Annual Meeting, Lisbon, Portugal, October, 21st-23th, 2017, Title: Comprehensive analysis of Sirtuin family expression in bladder urothelial carcinoma The International Bladder Cancer Network 15th Annual Meeting
IBCN (Lisboa, Portugal)
2017/05 READERS, WRITERS AND ERASERS- The Royal Society- Kavli Royal Society International Centre, Chicheley Hall, Buckinghamshire, UK, May 24 and 25th, 2017; Title: “Epigenetic biomarkers” READERS, WRITERS AND ERASERS
The Royal Society & COST Action CM1406 (Buckinghamshire, Reino Unido)
2017/03 Clinical Epigenetics International Meeting, Düsseldorf, Germany, March 9th –March 10th, 2017; Title: "Epigenetics of Prostate Cancer". Clinical Epigenetics International Meeting
Clinical Epigenetics Society (Düsseldorf, Alemanha)
2015/02 CANCER EPIGENETICS AND METABOLISM: Connecting the Dots, Cantanhede (Portugal), February 2-3th, 2015; Title: "Epigenetic deregulation in urological tumors: from biology to clinics" CANCER EPIGENETICS AND METABOLISM: Connecting the Dots
Biocant Park-Univ. Coimbra (Cantanhede, Portugal)
2014/10 22nd Meeting of the EAU Section of Urological Research (ESUR), Glasgow (UK), October 9-11 th, 2014; Title: “Development of epigenetic biomarkers for urological cancer detection and prognosis assessment”. 22nd Meeting of the EAU Section of Urological Research (ESUR)
EAU Section of Urological Research (ESUR) (Glasgow, Reino Unido)
2014/10 EMBO Workshop on Epigenetic plasticity: Implications in neural (dys)function, Braga (Portugal), October 22 – 25 th, 2014; Title: "Diagnostic and prognostic epigenetic biomarkers in cancer". EMBO Workshop on Epigenetic plasticity: Implications in neural (dys)function
ICVS-Univ. Minho (Braga, Portugal)
2014/08 IV International Symposium on Translational Oncology of the Barretos Cancer Hospital. Barretos, SP, (Brasil), September 19th to 20th, 2014; Title: “Exploiting epigenetic-based biomarkers: the paradigm of urological cancer”. IV International Symposium on Translational Oncology of the Barretos Cancer Hospital
Barretos Cancer Hospital (Barretos, Brasil)
2014/02/06 41th congress of the International Society of Oncology and Biomarkers & XIV International Symposium on Biology and Clinical Usefulness of Tumor markers. Barcelona (Spain), March 15– 18th, 2014; Title: “Epigenetics and Laboratory Medicine: Development of epigenetic biomarkers for urological cancer detection and prognosis assessment”. Lectures on Biomedicine-University of Córdoba & Maimonides Institute for Biomedical Research (IMIBIC)
IMIBIC (Cordoba, Espanha)
2014 Lectures on Biomedicine-University of Córdoba & Maimonides Institute for Biomedical Research (IMIBIC). Cordoba (Spain) February 6th, 2014; Title: “Epigenetics as a tool for cancer detection and prognosis/ prediction assessment”. 41th congress of the International Society of Oncology and Biomarkers & XIV International Symposium on Biology and Clinical Usefulness of Tumor markers
International Society of Oncology and Biomarkers (Barcelona, Espanha)
2013/10 COST-MEETING-TD0905-301013-035178. Vilnius (Lithuania), October 30, 31st 2013. Title: “Development of Epigenetic Biomarkers for Urological Cancer Detection” ECOST-MEETING-TD0905-301013-035178
ECOST-TD0905 (Vilnius, Lituânia)
2012/05 GRELL 2012-XXXVII Reunião do Grupo de Registos e de Epidemiologia de cancro dos países de Língua Latina, Porto (Portugal) May 16-18 th 2012; Title: “Immunohistochemistry as an auxiliary tool for oncology”. GRELL 2012-XXXVII Reunião do Grupo de Registos e de Epidemiologia de cancro dos países de Língua Latina
Registos e de Epidemiologia de cancro dos países de Língua Latina (Porto, Portugal)

Orientação

Título / Tema
Papel desempenhado
Curso (Tipo)
Instituição / Organização
2023 - Atual Evaluation of biomarkers in breast cancer patients undergoing mindfulness-based cognitive therapy
Orientador
Investigação Clínica e em Serviços de Saúde (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2022 - Atual Embracive - a microfluidio avinted technology for non-invase identification and characterization of extracellular veicles in bladder cancer patients
Orientador
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021 - Atual Prostate cancer pre-metastatic niche formation: exosomal osteotropism
Orientador
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020 - Atual Bladder cancer: tackling epigenetic players and immuno-oncology
Orientador
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020 - Atual Epitranscriptomic alterations within renal cancer metabolism reprogramming: uncovering new therapeutic targets
Orientador
Patologia e Genética Molecular (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - Atual DNA methylation biomarkers as detection and triage tools in population-based cervical cancer screening program
Orientador
Patologia e Genética Molecular (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2023 - 2023 G9a and EZH2: Epimarkers inTesticular Germ Cell Tumors
Orientador
Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022 - 2022 Plasma Extracellular Vesicles As a Source For Biomarkers or Recurrance, Progression  And  Treatment response in bladder Cancer
Coorientador
Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022 - 2022 Liquid Biopsies: Effects of Long-Time Storage
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022 - 2022 Cell-free DNA methylation as a biomarker for early detecting the four major cancers
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022 - 2022 Promoter methylation of DNA repair genes as biomarker of response to platinum-based chemotherapy: a pancancer investigation
Orientador
Bioquímica (Mestrado)
Universidade do Porto Faculdade de Ciências, Portugal
2018 - 2022 Epigenetic regulation of non-coding RNAs in Prostate Cancer
Orientador
Patologia e Genética Molecular (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016/09 - 2021/02 Role of vim in epithelial mesenchymal transition (EMT) in urothelial cancer
Orientador
Patologia e Genética Molecular (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021 - 2021 LiKidMiRS: unveiling the diagnostic potential of liquid biopsy-basedcirculating microRNAs in renal cell tumors
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021 - 2021 Immunoprofiling of Bladder Cancer: Setting the Basis for Novel Immunotherapeutic Strategies
Orientador
Bioquímica (Mestrado)
Universidade do Porto Faculdade de Ciências, Portugal
2021 - 2021 EFFECT OF MACROPHAGES IN PROSTATE CANCER CELL LINES´ TUMORIGENICITY
Orientador
Biotecnologia para as Ciências da Saúde (Mestrado)
Universidade de Trás-os-Montes e Alto Douro Escola de Ciências da Vida e do Ambiente, Portugal
2015 - 2020/09 Exploring epigenetic profiling as prognostic/predictive markers of endocrine resistance in estrogen receptor positive breast cancer
Orientador
Medicina e Oncologia Molecular (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2020 - 2020 2D versus 3D Models: Effect of CM-272 on Prostate Cancer Cell Lines
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020 - 2020 Role of SPARC derived peptides on endothelial/prostate cancer cells monoculture and co-culture models
Coorientador
Bioengenharia (Mestrado)
Universidade do Porto Faculdade de Engenharia, Portugal
2020 - 2020 MiR-30 family deregulation in ccRCC
Orientador
Medicina e Oncologia Molecular (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2020 - 2020 FOXA1 epigenetic regulation in breast cancer
Orientador
Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020 - 2020 Anti-neoplastic effect of MLo-1302 in Testicular Germ Cell Tumors: comparation with classical differentiating and demethylating agents, ATRA and DAC
Coorientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - 2019 Study of epigenetic silencing of the tumor suppressor gene SPINT2 in lung cancer
Coorientador
Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - 2019 Cell-free DNA methylation as a biomarker for early detection of the three major cancers in males
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - 2019 Clinical significance of ARID1A and ANXA1 in HER-2 positive breast cancer
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - 2019 Differential expression of cadherins in bladder cancer: role in epithelial-mesenchymal transition
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - 2019 Demethylation of the epigenetically silenced androgen receptor gene by a repurposed drug in castration-resistant prostate cancer cell lines
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - 2018 MIR-371A-3P AS A TOOL FOR SUBTYPING TESTICULAR GERM CELL TUMORS
Orientador
Genética Molecular Comparativa e Tecnológica (Mestrado)
Universidade de Trás-os-Montes e Alto Douro Escola de Ciências da Vida e do Ambiente, Portugal
2018 - 2018 Early detection of the three major primary cancers in women by cell-free DNA methylation in liquid biopsies
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - 2018 MicroRNA-30a hipermethylation as prognostic marker in clear cell renal all carcinoma.
Orientador
Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - 2018 Monocarboxylate Transporters (MCTs) in Kidney Cancer: The Role of Epigenetic Mechanism
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - 2018 Interplay between Warburg effect and epigenetic mechanisms in kidney cancer
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - 2018 Metastatic breast cancer: finding molecular biomarkers in liquid biopsies
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013/01 - 2017/06 MicroRNAs deregulation in prostate cancer
Orientador
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 A DNA-Methylation Signature by Multiplex Methylight for Prostate Cancer Diagnosis and Prognostication
Orientador
Medicina Molecular (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2017 - 2017 Decoding the usefulness of miRNAs as biomarkers in breast cancer patients treated with endocrine therapy
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 MicroRNA-27a-5p Regulation by Promoter Methylation and MYC Signaling in Prostate Carcinogenesis
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 Anti-neoplastic activity of newly synthetized DNMTi in urological tumors
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 A DNA-Methylation Signature by Multiplex Methylight for Prostate Cancer Diagnosis and Prognostication
Orientador
Medicina e Oncologia Molecular (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2017 - 2017 Histone post-translational modifications and chromatin remodelers in colorectal cancer
Orientador
Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 Circulating MicroRNAs as Markers of Prostate Cancer Progression: a Time-based Approach
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2009 - 2017 Development of new epigenetic-based biomarkers for renal cell tumors with clinical application
Coorientador
Medicina e Oncologia Molecular (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2008 - 2017 Carcinoma do endométrio: estudo de características patológicas e epigenéticas/Endometrial carcinoma: study of pathological and epigenetic characteristics
Coorientador de Carla Maria Magno Bartosch
Medicina e Oncologia Molecular (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2016 - 2016 Methylome of breast cancer molecular subtypes: diagnosis and prognosis biomarkers
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016 - 2016 Role of Chromatin Remodelers in Metastization of Renal Cell Tumors
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016 - 2016 Epigenetic Study of Colorectal Cancer: lncRNAs and CIMP Profiling
Orientador
Bioquímica (Mestrado)
Universidade do Porto Faculdade de Ciências, Portugal
2016 - 2016 DNA Methylation for Detection of Primary Colorectal Tumors
Orientador
Bioquímica (Mestrado)
Universidade do Porto Faculdade de Ciências, Portugal
2015 - 2015 MicroRNA promoter methylation: potential biomarkers in prostate cancer Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2008/10 - 2014/02 Impact of epigenetic modulators on the malignant phenotype of prostate cancer cells
Orientador
Patologia e Genética Molecular (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2008/10 - 2014/02 Histone methylases and demethylases: the role of SMYD3 in prostate carcinogenesis
Coorientador de Ana Filipa Quintela Vieira
Patologia e Genética Molecular (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2014 - 2014 The Functional role of histone methylation deregulation in renal tumorigenesis
Coorientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2014 - 2014 Uncovering PRMT6 deregulation effect in prostate cancer
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2014 - 2014 Exploiting the interplay between c.-Myc and novel micrornas in prostate carcinogenesis
Orientador
Bioengenharia (Mestrado)
Universidade do Porto Faculdade de Engenharia, Portugal
2006 - 2014 Expression changes of the ETS family of transcription factors associated with chromosome rearrangements in breast cancer
Coorientador de Bárbara Alexandra de Sousa Mesquita
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013 - 2013 MicroRNAS Profile: a Promising Ancillary Tool for Accurate Renal Cell Tumor Diagnosis
Coorientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013 - 2013 The Role of a Panel of Three Epigenetic Biomarkers in the Detection and Prognosis of Upper Urinary Tract Urothelial Carcinoma
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013 - 2013 The Role of a Panel of Three Epigenetic Biomarkers in the Detection and Prognosis of Upper Urinary Tract Urothelial Carcinoma
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013 - 2013 The Role of MIR-375 in Prostate Carcinogenesis
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2012 - 2012 Expression of histone modifying enzymes and histone post-translational marks in colorectal cancer
Coorientador
Medicina e Oncologia Molecular (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2012 - 2012 Epi-drugs regulate H2A.Z via SIRT1 upregulation in prostate cancer
Orientador
Bioquímica clínica (Mestrado)
Universidade de Aveiro Departamento de Química, Portugal
2012 - 2012 Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer
Coorientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2012 - 2012 Epigenetic regulation of micrornas in prostate cancer
Coorientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2012 - 2012 The role of insulin resistance in metabolic reprogramming and lineage commitment
Coorientador
Biologia Básica e Aplicada (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2011 - 2011 Assessment of enoxacin effect on cancer growth and microrna expression in prostate cell lines
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2011 - 2011 Role of Class I histone deacetylases in bladder carcinogenesis
Orientador de Susana Maria Pereira Junqueira Pacheco Neto
Oncologia
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2007 - 2011 Fusion oncogenes involving the ETS family of transcription factors in prostate cancer: target genes and clinical applications
Coorientador de Paula Cristina Martins Santos Paulo
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2007/01 - 2010/12 Development of Epigenetic-based Markers for Molecular Detection of Urological Cancers.
Orientador de Vera Lúcia Marques Costa
Ciências Biomédicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2010 - 2010 Analysis of PAX2 gene alterations in renal cell tumors
Orientador
Genética Molecular e Biomedicina (Mestrado)
Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia, Portugal
2010 - 2010 Identification and characterization of a novel epigenetic biomarker for prostate: the EFEMP 1 story
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2009 - 2009 Prognostic Value Of Methylation Markers In Breast Cancer
Orientador
Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2009 - 2009 Epigenetic and genetic alterations of DPYD are not predictive of severe toxicity to 5-Fluorouracil-based chemotherapy in gastrointestinal cancer
Orientador
Medicina e Oncologia Molecular (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2009 - 2009 Functional and epigenetic characterization of KTN19 in renal neoplasms
Coorientador
Bioquímica (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2009 - 2009 Epigenetic and functional characterization of OPCML gene in bladder carcinoma
Orientador
Bioquímica (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2009 - 2009 Epigenetic Markers as a Tool for Reducing Diagnostic and Treatment Burden in Wilms Tumor
Orientador
Medicina e Oncologia Molecular (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação)
Instituição / Organização
2023/11/09 - 2023/11/09 IPO Porto Research Center; 1st Young Researchers' Day (2023/11/09 - 2023/11/09)
Encontro (Presidente da Comissão Organizadora)
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2023/02/13 - 2023/02/14 7th Symposium of the Master in Oncology (videoconference), Porto, 13 & 14 of February 2023; Organizer & Scientific Chair (2023/02/13 - 2033/02/14)
Simpósio (Presidente da Comissão Organizadora)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2022/02/14 - 2022/02/15 6th Symposium of the Master in Oncology (videoconference), Porto, 14 & 15 of February 2022; Organizer & Scientific Chair (2022/02/14 - 2022/02/15)
Simpósio (Presidente da Comissão Organizadora)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2021/10/14 - 2021/10/15 II ASPIC-ASEICA International Meeting - Current Trends in Precision Medicine in Cancer, 14-15 October, (Virtual), 2021; Organizer & Scientific Committee (2021/10/14 - 2021/10/15)
Congresso (Coorganizador)
Associação Portuguesa de Investigação em Cancro, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2021/05/03 - 2021/05/03 European Cancer Research Summit https://ipoporto.pt/wpsite_2020/wp-content/uploads/2021/03/ECR2021_Programa.pdf (2021/05/03 - 2021/05/03)
Conferência (Membro da Comissão Organizadora)
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Fundação para a Ciência e a Tecnologia, Portugal
2021/02/22 - 2021/02/23 5 th Symposium of the Master in Oncology (videoconference), Porto, 22 & 23 of February 2021; Organizer & Scientific Chair (2021/02/22 - 2021/02/23)
Simpósio
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2020/02/17 - 2020/02/18 4th Symposium of the Master in Oncology, Porto, 17 & 18 of February, 2020; Organizer & Scientific Chair (2020/02/17 - 2020/02/18)
Simpósio
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2019/10 - 2019/10 26th Meeting of EAU Section of Urological Research (ESUR19), Porto, 10-12 October, 2019; Organizer & Scientific Chair (2019/10)
Congresso (Presidente da Comissão Organizadora)
European Association of Urology, Países Baixos

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2019/04 - 2019/04 3rd Symposium of the Master in Oncology, Porto, 15 & 16 of April, 2019; Organizer & Scientific Chair (2019/04)
Simpósio (Presidente da Comissão Organizadora)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2019/01 - 2019/01 CM1406 EpiChemBio Joint WorkGroup Meeting (WG2&3) Epigenetic reprogramming and epigenetic technologies, Paris, France 21-22 January 2019; Co-organizer (2019/01)
Conferência (Coorganizador)
2018/05 - 2018/05 2nd Symposium of the Master in Oncology, 7-8 May 2018; Organizer & Scientific Chair (2018/05)
Simpósio (Presidente da Comissão Organizadora)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017/09 - 2017/09 Joint EpiChemBio and MuTaLig COST Actions Meeting, Porto, Portugal, September 22-24, 2017); Co-chair (2017/09)
Congresso (Coorganizador)
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2017/04 - 2017/04 1st Symposium of the Master in Oncology, 10-11 April 2017; Organizer & Scientific Chair (2017/04 - 2017/04)
Simpósio (Presidente da Comissão Organizadora)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016/04 - 2016/04 Second ASPIC International Congress; Porto, Portugal, April 28, 29, 2016); Co-chair of the scientific committee (2016/04 - 2016/04)
Congresso (Coorganizador)
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2016/04 - 2016/04 Advanced Course in Immuno-oncology, Porto, Portugal, April 27, 2016; Co-organizer (2016/04 - 2016/04)
Congresso (Membro da Comissão Científica)
Associação Portuguesa de Investigação em Cancro, Portugal
2014/11 - 2014/11 First ASPIC International Congress, Lisbon, Portugal, November 25,26, 2014; Scientific Co-chair (2014/11 - 2014/11)
Congresso (Membro da Comissão Científica)
Associação Portuguesa de Investigação em Cancro, Portugal
2012/10 - 2012/10 A One Day Symposium with Carlos Caldas sponsored by EACR, Porto, Portugal, October 29, 2012; Member of the organizing scientific committee (2012/10 - 2012/10)
2011/01/28 - 2011/01/29 Second Meeting of the European Consortium-EpiDiaCan, Porto, 28th -29th January, 2011; Organizer & Scientific Chair (2011/01)
Conferência (Presidente da Comissão Organizadora)
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Júri de grau académico

Tema
Tipo de participação
Nome do candidato (Tipo de grau)
Instituição / Organização
2023/11 OPPONENT IN AGGREGATION EVALUATION COMMITTEE; Health Sciences; School of Medicine, University of Minho; Candidate: Fernanda Cristina Gomes Sousa Marques
Arguente principal
Fernanda Cristina Gomes Sousa Marques (Agregação)
Universidade do Minho Escola de Ciências da Saúde, Portugal
2023 PhD in Biology, School of Sciences, University of Minho, Braga, Portugal; Title: Towards valorization of beehive natural products: unravelling Portuguese propolis bioactivities and potential; Student: Ana Sofia Pereira de Freitas
Arguente principal
Ana Sofia Pereira de Freitas (Doutoramento)
Universidade do Minho Escola de Ciências, Portugal
2022 PhD in Molecular Biosciences, Autonomous University of Madrid, Spain; Title: Understanding bladder cancer through mouse models and epigenetic targets; Student: Ester Munera Maravilla
Arguente principal
Ester Munera Maravilla (Doutoramento)
Universidad Autonoma de Madrid Facultad de Ciencias, Espanha
2022 PhD in Translational Medicine; School in Life Sciences, Università degli studi della Campania Luigi Vanvitelli, Naples, Italy (External Evaluator for European Degree); Title: Exosome Functionalization in Acute Myeloid Leukemia; Student: Crescenzo Massaro
Vogal
Crescenzo Massaro (Doutoramento)
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Medicina di Precisione, Itália
2022 PhD in Health Sciences, School of Medicine, University of Minho, Braga, Portugal; Title: Characterization of the anticancer efficacy and safety profiles of novel synthetic compounds; Student: Olívia Alexandra Pontes
Arguente principal
Olívia Alexandra Pontes (Doutoramento)
Universidade do Minho Escola de Ciências da Saúde, Portugal
2021 PhD in Translational Medicine; European Degree, School in Life Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; Title: Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis: development of a Predictive Score and a risk stratification tool; Student: Antonella Riccardi
Arguente principal
Antonella Riccardi (Doutoramento)
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Medicina di Precisione, Itália
2021 PhD in Translational Medicine; European Degree, School in Life Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; Title: Mechanism of Resistance to EGFR-targeted therapies; Student: Nunzia Matrone
Arguente principal
Nunzia Matrone (Doutoramento)
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Medicina di Precisione, Itália
2021 PhD in Translational Medicine; European Degree, School in Life Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; Title: RAS mutant allele fraction in plasma predicts response to anti-angiogenic based first-line treatment in metastatic colorectal cancer; Student: Giulia Martini
Arguente principal
Giulia Martini (Doutoramento)
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Scienze Mediche Traslazionali, Itália
2021 PhD in Translational Medicine; European Degree, School in Life Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; Title: Mulple Roles of AXL Receptor Tyrosine Kinase in Colorectal Cancer Developmen; Student: Bernadette Lauensteine
Arguente principal
Bernadette Lauensteine (Doutoramento)
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Scienze Mediche Traslazionali, Itália
2019 PhD in Translational Medicine; European Degree, School in Life Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; Title: Unraveling the oncogenic role of CBX2 in human Leukemia: mechanisms regulating its protein stability and functional activity; Student: Lidio Conti
Arguente principal
Lidio Conti (Doutoramento)
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Scienze Mediche Traslazionali, Itália
2019 PhD in Biochemistry and Biotechnology; Faculty of Pharmaceutical, Biomedical and Veterinary Sciences (FBD) - University of Antwerp, Belgium; Title: Epigenetic profiling of adverse lifestyle conditions and nutraceutical interventions in health and disease; Student: Ken Declerck
Arguente principal
Ken Declerck (Doutoramento)
Universiteit Antwerpen Departement Biochemie and Biotechnologie, Bélgica
2019 PhD in Chemistry-Catalysis and Sustainability Specialization, University of Coimbra, Coimbra, Portugal; Title: Development of Metal Catalysts for Activation of CO andCO2.Synthesis of Small Ring Heterocycles with Potential Biological Activity; Student: Ana Sofia Pereira de Freitas
Arguente principal
Lucas Danilo Dias (Doutoramento)
Universidade de Coimbra Departamento de Engenharia Quimica, Portugal
2019 PhD in Cellular Signaling, Faculty of Medicine and Health Sciences, University of Alcalá, Madrid, Spain; Title: Preclinical study of potential therapeutic strategies based on epigenetics for bladder cancer; Student: Cristina Segovia de Andrés
Arguente principal
Cristina Segovia de Andrés (Doutoramento)
Universidad de Alcalá Facultad de Medicina y Ciencias de la Salud, Espanha
2017 PhD in Translational Medicine; School in Life Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy (External Evaluator for European Degree); Title: The Emerging Role of tumor-derived exosomes in Acute Myeloid Leukemia; Student: Cristina Giorgio
Arguente
Cristina Giorgio (Doutoramento)
Università degli Studi della Campania Luigi Vanvitelli Dipartimento di Scienze Mediche Traslazionali, Itália
2017 PhD in Biomedical Sciences; University of Vilnius, Lithuania (External Evaluator for European Degree); Title: The Emerging Role of tumor-derived exosomes in Acute Myeloid Leukemia; Student: Kristina Daniunaite
Arguente
Kristina Daniunaite (Doutoramento)
Vilniaus kolegija, Lituânia
2017 PhD in Health Sciences, School of Health Sciences, University of Minho, Braga, Portugal; Title: Monocarboxylate Transporters (MCTs) in breast cancer aggressiveness: therapeutic targeting and regulatory mechanisms; Student: Luisa Filipa Morais dos Santos.
Arguente principal
Luisa Filipa Morais dos Santos (Doutoramento)
Universidade do Minho Escola de Ciências da Saúde, Portugal
2016 PhD in Genetics; Department of Genetics; University of Córdoba, Spain; Title: DNA demethylation through 5-methylcytosine excision. Molecular basis and potential applications; Student: Jara Teresa Parrilla Doblas
Arguente principal
Jara Teresa Parrilla Doblas (Doutoramento)
Universidad de Córdoba Facultad de Ciencias, Espanha
2016 PhD in Health Sciences branch of Biomedical Sciences; Faculty of Medicine, University of Coimbra, Portugal; Title: Oxidative stress versus epigenetic– Role in susceptibility, development, and progression of myeloid neoplasms; Student: Ana Cristina Pereira Gonçalves
Arguente principal
Ana Cristina Pereira Gonçalves (Doutoramento)
Universidade de Coimbra Faculdade de Medicina, Portugal
2016 PhD in Pharmaceutical Sciences; School of Pharmaceutical Sciences; University of Geneve, Switzerland; Title: EZH2 induces methylation of ERG enhancing its transcriptional and transforming activity; Student: Laura Curti
Arguente principal
Laura Curti (Doutoramento)
Université de Genève Faculté des Sciences, Suiça

Université de Genève, Suiça
2016 PhD in Veterinary Sciences; Faculty of Veterinary, University of Lisbon, Portugal; Title: The role of JAGGED1 in adult angiogenesis and in solid tumor development; Student: Ana Rita Ponce Álvares de Águeda Pedrosa
Arguente principal
Ana Rita Ponce Álvares de Águeda Pedrosa (Doutoramento)
Universidade de Lisboa Faculdade de Medicina Veterinária, Portugal
2015 PhD in Biomedicine, Faculty of Health Sciences, Univ. of Beira Interior (UBI), Covilhã, Portugal; Title: Androgens and Calcium-binding protein Regucalcin in the control of Prostate cells metabolism and survival: implications in Carcinogenesis; Student: Cátia Alexandra Vicente Vaz
Arguente principal
Cátia Alexandra Vicente Vaz (Doutoramento)
Universidade da Beira Interior Faculdade de Ciências da Saúde, Portugal
2015 PhD in Biomedical Sciences specialty Biopathological Sciences, Faculty of Medicine, University of Lisbon, Portugal; Title: Effects of chemotherapy and radiotherapy in rectal cancer: significance of different cellular outcomes in tumor behavior; Student: Joana Maria Tato Ribeiro da Costa
Arguente principal
Joana Maria Tato Ribeiro da Costa (Doutoramento)
Universidade de Lisboa Faculdade de Medicina, Portugal
2015 PhD in Health Sciences and Technology, speciality in Cellular and Molecular Biology of the Faculty of Pharmacy, University of Coimbra, Portugal; Title: Long non-coding RNAs at the service of p53; Student: Carlos Manuel Almeida Guedes de Melo
Arguente principal
Carlos Manuel Almeida Guedes de Melo (Doutoramento)
Universidade de Coimbra Faculdade de Farmácia, Portugal
2014 PhD in Health Sciences, School of Health Sciences, University of Minho, Braga, Portugal; Title: Transcription Factors and Epigenetics in breast: new findings in CDH3/P cadherin Gene regulation; Student: André João Almeida Marques Soares de Albergaria.
Arguente principal
André João Almeida Marques Soares de Albergaria (Doutoramento)
Universidade do Minho Escola de Ciências da Saúde, Portugal
2014 President of the juries of the MSc In Oncology 2014-2023: 78 Masters
Presidente do júri
MSc Students (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2022 - Atual Frontiers in Genetics
2022 - Atual Frontiers in Cell and Developmental Biology
2014 - Atual Clinical Epigenetics (1868-7083) Springer-Verlag
2019 - 2024 Guest Editor of the Topical Collection "Germ Cell Tumors"-CANCERS MDPI

Comissão de avaliação

Descrição da atividade
Tipo de assessoria
Instituição / Organização Entidade financiadora
2014 - Atual Evaluation committee of FCT Investigator call- 2013 e 2015
Avaliador
Fundação para a Ciência e a Tecnologia, Portugal Fundação para a Ciência e a Tecnologia
2014 - Atual Evaluation committee of EU_COST OC-2014-1(European Cooperation in Science and Technology
Avaliador
European Cooperation in Science and Technology, Bélgica
2003 - Atual Evaluation of scientific Grants: 2003-Health Research Board,IR 2006-Associazione Italiana per la Ricerca sul Cancro 2006,2007-National Medical Research CouncilSingapore 2007, 2012,2015, 2019-Cancer ResearchWILLIAMS BARKER, MRC,UK; 2011,2016, 2018,2022, 2023 -Swiss National Science Foundation; 2013,2015-Swiss League Against Cancer; 2013,2015-Austrian Science Fund; 2014, 2020-PROSTATE CANCER UK 2016,2017,2023-Fund for Scientific ResearchBL; 2019-Fundaciò MaratóSP, 2022-Institut National Du Cancer, FR; 2023-Novo Nordik Foden Laureate Research G,NO
Avaliador
Health Research Board (HRB)-Ireland, Irlanda

Associazione Italiana per la Ricerca sul Cancro, Itália

National Medical Research Council, Singapura

Cancer Research UK, Reino Unido

Binational Science Foundation, Israel

Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung, Suiça

Swiss League Against Cancer, Suiça

Fonds zur Förderung der wissenschaftlichen Forschung, Áustria

European Cooperation in Science and Technology, Bélgica

Agence nationale de la recherche, França

Fundació la Marató de TV3, Espanha

Institut National du Cancer, França

Novo Nordik Foden , Noruega

Consultoria / Parecer

Descrição da atividade Instituição / Organização
2023/02/27 - Atual Pro bono, Scientific Consultant of Karion Therapeutics company, Braga, Portugal Karion Therapeutics, Portugal

Membro de associação

Nome da associação Tipo de participação
2015/01 - Atual European Association of Urology
2013/01/01 - Atual Portuguese Association for Cancer Research- EACR Afilliated Member
2002 - Atual European Association for Cancer Research
1999 - Atual American Association for Cancer Research
1992/01 - Atual Order of Biologists/Ordem dos Biólogos Member

Membro de comissão

Descrição da atividade
Tipo de participação
Instituição / Organização
2023/11 - Atual Chair of the European Association of Urology (EAU) Section of Urological Research ( ESUR)
Outro
European Association of Urology, Países Baixos
2022 - Atual Vice-President of the Portuguese Association for Cancer Research (ASPIC)
Presidente / Vice-presidente
Associação Portuguesa de Investigação em Cancro, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
2022 - Atual Management Committee member of the COST ACTION, entitled IMMUNO-model -Modelling Immunotherapy response and toxicity in Cancer- CA21135
Membro
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2021/10 - Atual Certified auditor of the Organisation of European Cancer Institutes
Outro
Organisation of European Cancer Institutes, Bélgica
2021/05 - Atual President of the North Delegation -Order of Biologists
2017 - 2021 Management Committee member of COST Action European Epitranscriptomics Network-CA16120-EPITRAN
Outro
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2015 - 2019 Management Committee member of Action Epigenetic Chemical Biology (EPICHEMBIO) CMST COST Action CM1406 and Chair of Working group WG2- Epigenetic Technology
Outro
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013/01/01 - 2016 Executive committee member; Treasurer of ASPIC -Portuguese Association for Cancer Research
Outro
Associação Portuguesa de Investigação em Cancro, Portugal
2013 - 2016 Management Committee member of Action TD0905- Chemistry and Molecular Sciences and Technologies (CMST) - Epigenetics: Bench to Bedside, member WG4
Outro
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Distinções

Prémio

2004 Scholar in training award (co-authorship)-AACR
American Association for Cancer Research, Estados Unidos

Outra distinção

2007 1ª Menção Honrosa do Prémio LabMED 2006
2007 2ª Menção Honrosa do Prémio LabMED 2006
2005 1ª Menção Honrosa do Prémio LabMED 2004